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General remarks 
1 
General remarks 
Introduction 
Pathological symptoms of digestive tract, such us heartburn, loss of appetite, eructation, nausea, 
vomiting, epigastric pain, and perceived gastric swelling, are referred to as indefinite epigastric 
pain. These complaints have been suggested to be caused by motility disorders in the upper 
digestive tract (esophagus, stomach, and small intestine). 
In particular, attention has focused on a disorder termed functional dyspepsia. In recent years, 
methods for measuring motility in the digestive tract have been developed, and delayed gastric 
emptying have also been observed in approx. 30-75% in functional dyspepsia patients (Kellow 
et al., 2000). Namely, delay in gastric emptying might cause indefinite epigastric complaints in 
functional dyspepsia. Furthermore, peristaltic abnormalities have been widely observed in 
diabetes patients and are thought to be due to a delayed gastric emptying caused by peripheral 
and autonomic nerve disorders. The gastric emptying is abnormally slow in approx. 30-50% of 
outpatients which long-standing Type 1 or Type 2 diabetes (Horowitz et al., 2002). In diabetes, 
these problems can result in digestive tract complications which are major concern. 
Drugs for treating the above symptoms are termed gastroprokinetic agents (Scarpignato, 1996). 
These drugs stimulate gastric motility, reducing the delay in gastric emptying and thus 
improving the symptoms. The prokinetic agents currently on the market can be classified into 
two main groups on the basis of their mechanisms of action, namely, serotonin agonists such as 
cisapride, and dopamine antagonists such as metoclopramide and domperidone. These drugs are 
widely used for treating abnormalities of the digestive tract, especially indefinite epigastric 
complaints caused by decreased peristalsis. However, dopamine antagonists have a risk of 
causing extrapyramidal reactions and hyperprolactinaemia (Tonini et al., 2004). Cisapride has 
also been reported to have a potential risk of causing fatal arrhythmia (Wysowski et al., 2001). 
Furthermore, peristalsis stimulated by these drugs is different from naturally occurring 
peristalsis, which propagates from the upper to the lower part of the digestive tract. As a result 
of this difference, side effects such as vomiting and diarrhea may frequently occur. 
 
Motilin, a linear 22-amino acid polypeptide of 2,700 Dalton first characterized and isolated from 
the porcine small intestinal mucosa (Brown et al., 1971, 1973), has been found to localize in 
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endocrine cells of the gastrointestinal mucosa in a number of species, including the human 
(McIntosh and Brown, 1990). The chemical structure of motilin has now been elucidated in 
other species including monkey (Huang et al., 1998), dog (Poitras et al., 1983), cat (Depoortere 
et al., 1993a), and rabbit (Banfield et al., 1992), as shown Figure 1.  
 
 
 
Figure 1 Amino acid sequence of 
motilin in various species. 
 
In the interdigestive (fasted) state, motilin is periodically released and this release is associated 
with phase III activity of the migrating motor complex (MMC) (Figure 2, Itoh and Sekiguchi, 
1983). To date, a number of investigators have demonstrated that motilin causes contraction of 
the isolated gastrointestinal muscle in several species (Strunz et al., 1975; Poitras et al., 1987; 
Depoortere et al., 1993b) and exogenous motilin initiates periods of contractile activity that are 
similar to the MMC, namely motilin initiates well-coordinated contractions throughout the 
gastrointestinal tract in conscious dogs and humans (Itoh et al., 1976; Vantrappen et al., 1979). 
Thus, motilin may improve the motility disorder, especially hypo-motility disorder associated 
with many types of illness. However, as mentioned above, motilin is a peptide, so development 
for oral use has been difficult. 
 
 
Figure 2 MMC pattern in the canine 
gastrointestinal tract and cyclic 
pattern of plasma motilin levels. 
During the interdigestive state, the plasma 
motilin concentration fluctuates at about 100-
min intervals and each peak of the motilin 
concentration coincides with the end of band of 
strong contractions (phase III activity) in the 
gastric antrum. Reprinted from Itoh and 
Sekiguchi (1983).  
 
In 1984, it was discovered that erythromycin mimics the effect of motilin and induces phase III 
which start in the stomach (Itoh et al., 1984). Further pharmacology studies have shown that 
erythromycin and other 14-member macrolides exhibit a motilin-like effect on the 
1-5 6-10 11-15 16-20 21-22
Pig/Human FVPIF TYGEL QRMQE KERNK GQ
Monkey FVPIF TYGEL QRMQE KERSK GQ
Dog FVPIF THSEL QKIRE KERNK GQ
Cat FVPIF THSEL QRIRE KERNK GQ
Rabbit FVPIF TYSEL QRMQE RERNR GH
Consensus FVPIF T• • EL Q • • • E • ER • • G • 
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gastrointestinal tract, both in in vivo and in in vitro conditions (Itoh, 1997; Peeters, 2006) via 
motilin receptors, since erythromycin can displace 125I-labeled motilin bound to the receptor 
(Peeters et al, 1989; Hasler et al., 1992). These findings led many investigators to evaluate the 
utility of erythromycin in treating certain gastrointestinal diseases associated with disordered 
gastric motility. Janssens et al. (1990) demonstrated that orally administered erythromycin was 
associated with improved gastric emptying in patients with diabetic gastroparesis.  
The receptor for motilin was recently isolated from human stomach, identified, and cloned 
(Feighner et al., 1999). Both erythromycin and motilin interacted with the cloned receptor, 
providing a molecular basis for its effect on the human gastrointestinal tract. However, 
erythromycin is acid-labile, is of low potency and possesses antibiotic activity, which could 
result in antibiotic resistance or overgrowth of nonsusceptible organisms if administered 
chronically, and is often poorly tolerated when administered by the oral route. Many derivatives 
with potent motor stimulating activity but no antibacterial activity have therefore been 
synthesized in the hope of ameliorating motility disorders in patients with idiopathic, diabetic, 
post-operative, or chemotherapy-induced gastroparesis (Ōmura et al., 1987; Faghih et al., 1998). 
Unfortunately, most of these erythromycin derivatives rapidly degrade in acidic pH as in the 
stomach (Koga et al., 1994). Thus, with those limitations of erythromycin, mentioned above in 
mind, efforts were initiated to develop an acid-resistant erythromycin-like compound 
(erythromycin derivative) with high prokinetic activity but are devoid of antibacterial activity. 
Mitemcinal (Figure 2-1) was the product of these efforts. The aim of this work was to clearly 
demonstrate the pharmacological profiles of this novel motilin receptor agonist and its efficacy.  
 
Summary of this study 
In order to assess the functional and physiological roles of motilin and motilin receptor agonists, 
a selective motilin antagonist may be a useful pharmacological tool. At the initiations of this 
study, however, since pure and selective motilin receptor antagonists were unavailable, the 
novel motilin receptor antagonist GM-109, which is a cyclic peptide (Figure 1-1), was 
synthesized. The properties of GM-109 were examined and the results of experiments indicated 
that GM-109 is a selective motilin receptor ligand that lacks agonistic properties but acts as a 
pure antagonist (Chapter I). GM-109 was used for the subsequent examinations as a useful 
pharmacological tool.  
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In Chapter II, the pharmacological profiles of mitemcinal-induced effects on the small intestine 
isolated from rabbits were investigated and compared these effects with those of porcine motilin, 
erythromycin A (EMA) and its derivatives (EM-523, EM-574, and ABT-229). Furthermore, the 
acid-resistant property of mitemcinal was evaluated. The results demonstrated that mitemcinal is 
a selective and full motilin receptor agonist in the smooth muscle of the rabbit small intestine 
and that this agent has an excellent acid-resistant property. 
 
The pharmacological profiles including acid-resistant property of mitemcinal was confirmed in 
in vitro study (Chapter II), then the efficacy of mitemcinal in vivo was investigated and 
compared those effects with those of porcine motilin and EMA derivatives (EM-523 and EM-
574) in conscious dogs. The results demonstrated that mitemcinal-induced gastrointestinal 
contractile activity operates via motilin receptors and possesses a higher activity than EM-523 
and EM-574 when administered orally in the digestive state (Chapter III). 
 
Although a numerous number of studies have demonstrated that motilin and motilin receptor 
agonists including erythromycin and its derivatives show potent motility-stimulating activity in 
the upper gastrointestinal tract, there are few reports investigated the effects on lower 
gastrointestinal motility and its stimulating effect remains controversial. Therefore, the effects 
of oral administration of mitemcinal on colonic motility and bowel movement in conscious dogs 
were investigated. The results demonstrated that mitemcinal stimulates colonic motility via 
motilin receptors and colonic motility may reflect bowel movement after feeding (Chapter IV). 
 
There are several differences in the actions of motilin in different species and under different 
experimental conditions, and most of the preclinical studies for motilin and motilin receptor 
agonists have mainly used dogs (in vivo) and rabbits (in vitro). It may be difficult to predict the 
effects of erythromycin derivatives in humans based on preclinical results in dogs or rabbits. So, 
the actions of motilin and mitemcinal on the gastrointestinal tract, both in vivo and in vitro were 
investigated in Rhesus monkeys. In in vivo investigations, mitemcinal induced MMC-like 
contractions. In in vitro investigations, mitemcinal contracted isolated duodenum strips in a 
concentration-dependent manner. Thus, Rhesus monkeys may be useful for studying the 
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physiological and pharmacological roles of the motilin agonistic mechanism because they show 
reactivity to motilin both in in vivo and in vitro (Chapter V).  
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1. GM-109: A Novel, Selective Motilin Receptor Antagonist in the 
Smooth Muscle of the Rabbit Small Intestine 
1.1 Introduction 
Motilin, a 22-amino-acid polypeptide first characterized and isolated from the porcine small 
intestinal mucosa (Brown et al., 1971, 1973), has been found to localize in endocrine cells of the 
gastrointestinal mucosa in a number of species, including the human (McIntosh and Brown, 
1990). Although the precise physiological role of motilin has not been completely defined, a 
number of investigators have demonstrated that motilin causes contraction of the isolated 
gastrointestinal muscle in several species (Strunz et al., 1975; Poitras et al., 1987; Depoortere et 
al., 1993b; Yogo et al., 1994) and initiates periods of contractile activity that are similar to the 
MMC in conscious dogs, monkeys, and humans (Itoh et al., 1976; Yogo et al., 1994; Vantrappen 
et al., 1979). However, in order to assess motilin’s functional and physiological roles, a selective 
motilin antagonist is required. A selective motilin antagonist (ANQ-11125) has recently been 
described (Peeters et al., 1994), but its chemical structure has not been reported, and it has not 
been unequivocally identified as a pure and selective antagonist because at high concentrations 
it acted as a partial agonist, causing contractions of the rabbit duodenum. Therefore, in order to 
definitively investigate the role of motilin receptor activation, we synthesized the novel motilin 
receptor antagonist GM-109, which is a cyclic peptide (Figure 1-1; Murayama and Haramura, 
1993). In the present study, we describe the properties of GM-109 and the results of experiments 
indicating that GM-109 is a selective motilin receptor ligand that lacks agonistic properties but 
acts as a pure antagonist in the smooth muscle of the rabbit small intestine. 
Chapter I: GM-109, a motilin antagonist 
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Figure 1-1  Chemical structure of GM-109. MW is 679.73. 
 
1.2 Materials and methods 
1.2.1 Procedures for recording contractile activity 
Male Japanese-White rabbits (about 3 kg) were used. The animals were anesthetized with 
thiopental sodium (30 mg/kg, i.v.) and exsanguinated. The upper part of the small intestine was 
rapidly removed after laparotomy and placed in an ice-cold modified Krebs’ solution composed 
of (in mM): NaCl 120.0, KCl 4.7, CaCl2 2.4, KH2PO4 1.0, MgSO4 1.2, NaHCO3 24.5, and 
glucose 5.6 (pH 7.4). The duodenum was washed, freed from mesenterical attachment and cut 
along the longitudinal axis to obtain muscle strips approximately 10 mm long and 3 mm wide. 
The preparation was mounted in an organ bath containing 10 mL of modified Krebs’ solution 
kept at 28 ºC to prevent excessive spontaneous contractions (Adachi et al., 1981). The solution 
was gassed with a mixture of 95% O2 and 5% CO2. The longitudinal strips were initially loaded 
with a 1.0-g weight, and contractile activity was measured by means of isotonic transducers 
(ME-4012, Medical Electronics Co., Tokyo, Japan) and recorded on an ink-writing recorder 
(Type 3066, Yokogawa-Denki, Tokyo, Japan). Before the experiments, each strip was subjected 
to repeated stimulation with 100 µM ACh until a reproducible response was obtained. In rabbit 
isolated small intestinal muscle strips, porcine motilin (pMTL) caused a biphasic contraction: an 
initial phasic contraction followed by a slowly fading contraction (tonic contraction) (Adachi et 
al., 1981; Matthijs et al., 1989). In the first experiment, therefore, in order to analyze whether 
GM-109 affects the tonic contraction induced by pMTL, we observed the contractile response to 
10 nM pMTL over a 30-mm period in the absence or presence of 10 µM GM-109. In the second 
experiment, cumulative concentration-dependent contractile curves for pMTL (0.1-100 nM), 
Chapter I: GM-109, a motilin antagonist 
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ACh (0.01-100 µM), SP (0.1-300 nM), PGF2α, (1 nM-10 µM), and KCl (10-100 mM) were 
established by adding increasing concentrations of each compound and calculating the pD2 
value (the negative logarithm of the concentration that caused half-maximal contraction) (van 
Rossum and van den Brink, 1963). The effect of GM-109 on the contractile activity of each 
agonist was further studied by incubating the strip for 15 mm with different concentrations of 
GM-109 (0.1-3 µM) and then recording a cumulative concentration-response curve in the 
presence of GM-109. The pA2 value and slope were obtained by regression analysis of Schild 
plots as has been described previously (Arunlakshana and Schild, 1959). In order to normalize 
the data, we expressed the contractile potency of each agonist as a percentage of that induced by 
100 µM ACh. All drug concentrations are expressed as final molar (M) concentrations in the 
bath solution. 
 
1.2.2 Binding assay procedures 
Binding assay for motilin receptor was performed according to the procedure introduced by 
Bormans et al. (1986) with a slight modification. After exsanguination, the upper part of the 
small intestine (about 50 cm) of the rabbit was rapidly removed and rinsed with ice-cold 0.9% 
saline. The smooth muscle tissue was dissected free from connective tissue and mucosa, finely 
minced and homogenized in 50 mM Tris-HC1 buffer (pH 7.4) at 0 ºC using tapered tissue 
grinders (Wheaton, Miliville, NJ) at 2000 rpm for 30 sec. The homogenate was centrifuged at 
1500 g for 5 mm and was washed twice with a fresh buffer. The final pellet was resuspended in 
50 mL of 50 mM Tris-HCl buffer (pH 8.0, containing 10mM MgCl2, 1.5% bovine serum 
albumin) for binding studies. The protein concentration was determined by the method of Lowry 
et al. (1951) using bovine serum albumin as the standard. The homogenate (about 1.0 mg 
protein/assay) was incubated at 25 ºC for 120 mm with 25 pM 125I-pMTL (specific activity, 33-
66 kBq/pmol); the final volume was 1 mL. After incubation, the reaction was stopped by adding 
2 mL of cold buffer. Bound and free reagents were separated by centrifugation at 1500 g for 5 
mm. The pellet was washed with a cold buffer, and its radioactivity was determined with a 
gamma counter (ARC-300, Aloka, Tokyo, Japan). Specific binding was defined as the 
difference between total binding and nonspecific binding determined after the addition of 1 µM 
pMTL. Displacement curves were obtained by adding increasing amounts of pMTL or GM-109 
to the incubation sample. 
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1.2.3 Drugs 
GM-109 (Murayama and Hararnura, 1993) was synthesized in our organic chemistry laboratory. 
Other compounds and their sources were pMTL, PGF2α, and TFX (Sigma Chemical Co., St. 
Louis, MO), ACh (Daiichi Pharmaceutical Co., Tokyo, Japan), SP (Peptide Institute Inc., Osaka, 
Japan), and 125I-pMTL (Peninsula Laboratories Inc., Belmont, CA). PGF2α was first solubilized 
in absolute ethanol and then diluted with 0.9% saline. Other drugs were dissolved in 0.9% saline 
or distilled water. 
 
1.2.4 Statistical analysis 
Data are expressed as mean ± SEM. Statistical analysis was made by Student’s t test as 
appropriate, and P values less than .05 were considered statistically significant. 
 
1.3 Results 
1.3.1 Contraction studies 
The rabbit isolated longitudinal muscle strips showed a rhythmic spontaneous contraction 
superimposed on the base-line tonus. PMTL (10 nM) applied to the bathing fluid caused a rapid, 
initial phasic contraction followed by a slowly fading contraction (tonic contraction, Figure 
1-2A). The tonic contraction induced by pMTL declined very slowly, and recovery of the effect 
of pMTL was usually not accomplished in the presence of pMTL. When GM-109 (10 µM) was 
applied after the contraction by pMTL was fully established, the tonic contraction, previously 
established at approximately 70% of the phasic, returned rapidly to baseline before application 
of pMTL (Figure 1-2B). This relaxing activity of GM-109 was not affected by pretreatment with 
1 µM TTX (Figure 1-2C). On the other hand, GM-109, up to a concentration of 100 µM, did not 
affect the base-line tonus and did not induce contractions in duodenal muscle strips (Figure 
1-2D). 
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Figure 1-2  Typical tracing of contractions of rabbit duodenal strips induced by 
application of pMTL (10 nM) (A) and effects of GM-109 (10 µM) on the tonic 
contractions induced by pMTL (10 nM) in the absence (B) or presence (C) of TTX 
(1 µM). Typical tracing of contractions of rabbit duodenal strips after application 
of GM-109 (100 µM) (D). Numbers show the molar concentration of each drug in 
the organ bath. Horizontal bar shows 10 mm. 
 
The phasic contractions induced by increasing concentrations of pMTL alone and in the 
presence of 3 µM GM-109 are shown in Figure 1-3A and B. GM-109, which had no effect on 
the resting tone or spontaneous contractions (Figure 1-3B), induced a parallel rightward shift in 
the concentration-dependent contractile response curve for pMTL without significantly reducing 
its maximal contractile responses (Figure 1-4A). The pA2 value for GM-109 as an antagonist of 
pMTL was 7.37 ± 0.24, and the slope was 0.99 ± 0.09 (Figure 1-4B). In this experiment, 
however, a higher concentration of GM-109 (10 μM) did not significantly affect the 
concentration-dependent contractile response curve for ACh, SP, PGF2α, or KCl (Table 1-1). 
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Figure 1-3  Typical tracing of contractions of rabbit duodenal strips induced by 
cumulative application of pMTL in the absence (A) or presence (B) of GM-109. 
GM-109 (3 µM) was added to the bath 15 mm before application of pMTL. 
Numbers show the molar concentration of each drug in the organ bath. 
Horizontal bar shows 10 mm. 
 
 
 
 
 
 
 
Figure 1-4  (A) Concentration-response curves for pMTL-induced contractions in 
rabbit isolated duodenal strips in the absence (O) or presence of GM-109 (∆, 0.1 
µM; □, 0.3 µM; ●, 1 µM; ▲, 3 µM). The ordinate scale represents the percent of the 
contraction induced by 1 00 µM ACh. Each point represents the mean ± SEM 
from 6 to 10 preparations. (B) Schild analysis of antagonism by GM-109 of pMTL-
induced contractions in isolated rabbit duodenal strips. 
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Table 1-1  Effects of GM-109 (10 µM) on pD2 values and maximal contraction 
induced b y ACh, SP, PGF2α, and KCl in rabbit isolated longitudinal duodenum 
muscle strips. 
  Maximal Contraction 
 pD2 Value (% of 100 μM ACh) 
 Agonists Control (n) After GM-109 (n) Control (n) After GM-109 (n) 
 ACh 6.44 ± 0.14 (6) 6.39 ± 0.16 (6) 111.9 ± 2.8 (6) 106.8 ± 0.6 (6) 
 SP 8.27 ± 0.09 (6) 8.30 ± 0.08 (6) 96.0 ± 4.4 (6) 98.5 ± 2.6 (6) 
 PGF2α 6.55 ± 0.10 (7) 6.65 ± 0.06 (6) 61.8 ± 5.0 (7) 59.2 ± 4.5 (6) 
 KCl 1.45 ± 0.04 (7) 1.41 ± 0.03 (7) 89.7 ± 3.2 (7) 87.9 ± 4.2 (7) 
Each value represents the mean ± SEM. 
 
1.3.2 Binding assay 
Both GM-109 and unlabeled pMTL displaced 125I-pMTL bound to the homogenate of the 
smooth muscle of the rabbit small intestine in a concentration-dependent manner (Figure 1-5A). 
The pKi value of GM-109 and the pKd value of unlabeled pMTL were 7.99 ± 0.04 and 9.25 ± 
0.06 (each n = 5), respectively. The Hill coefficient values of GM-109 and pMTL, obtained from 
a logistic equation (Hill, 1910), were 0.96 ± 0.03 and 0.97 ± 0.04 (each n = 5), respectively. 
These results indicate that there is no major cooperation of the binding of GM-109 and pMTL. 
To determine whether GM-109 interacts competitively with motilin receptor, we carried out 
Scatchard analysis (Scatchard, 1949) of motilin binding in the presence or absence of GM-109. 
As shown in Figure 1-5B, the presence of GM-109 (10 nM) decreased the pKd value of 125I-
pMTL binding (control, 9.25 ± 0.06; presence of GM-109, 8.84 ± 0.05; P < .01; each n = 5) with 
no significant effect on the maximal binding capacity (Bmax) (control, 22.5 ± 1.9 fmol/mg 
protein; presence of GM-109, 23.1 ± 2.0 fmol/mg protein; not significant; each n = 5). This 
result indicates that GM-109 is a competitive inhibitor of motilin binding to the motilin receptor.  
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Figure 1-5  (A) Displacement of 125l-pMTL binding on the rabbit small intestinal 
tissue by GM-109 (●) and pMTL (○). Each point represents the mean ± SEM from 
five experiments. (B) Scatchard analysis of specific 125l-pMTL binding in the 
rabbit small intestinal tissue in the absence (○) and presence (●) of GM-109 at 10 
nM. This is a typical experiment and was repeated four times with similar results. 
 
1.4 Discussion 
The findings in the present contractile study show that GM-109 acts as a selective and 
competitive antagonist at the motilin receptor in the rabbit duodenum. The fact that GM-109 
interacts competitively with motilin receptor was also confirmed by binding studies. Both GM-
109 and unlabeled pMTL displaced 125I-pMTL bound to a homogenate of the rabbit small 
intestinal smooth muscle tissue in a concentration-dependent manner. The displacement curves 
of the two compounds were parallel, which indicates that GM-109 is a competitive inhibitor of 
motilin at the receptor level. Furthermore, in the Scatchard analysis, the presence of GM-109 
decreased the pKd value of 125I-pMTL binding with no significant effect on the Bmax value. This 
observation is compatible with a competitive antagonistic profile for GM-109.  
Recently, another compound, ANQ-11125, had been initially reported to exert competitive 
antagonism at the motilin receptor site in the rabbit gastric antrum and duodenum (Peeters et al., 
1994), even though ANQ-11125 induces contractions in the isolated rabbit duodenum at a higher 
concentration (10 μM). In contrast to ANQ-11125, GM-109, up to concentration of 100 μM, did 
not induce contractions in the rabbit duodenum, which indicates that GM-109 lacks agonistic 
activity and acts as a pure antagonist. The identification of a novel, selective and competitive 
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motilin receptor antagonist that lacks agonistic activity may significantly contribute to 
advancing our knowledge in the field of motilin receptors. 
According to the results of the present studies, the antagonistic activity of GM-109 to pMTL 
was unaffected by pretreatment with TTX (1 μM), which indicates that the action of GM-109 is 
mediated not by neural activities but by directly mediated effects on intestinal smooth muscle 
motilin receptors. This finding is consistent with previous reports (Domschke et al., 1976; 
Adachi et al., 1981; Satoh et al., 1990) in which, the contractile response to pMTL was found 
not to be affected by TTX, atropine, hexamethonium, mepyramine or naloxone in the isolated 
rabbit small intestine. These results suggested that rabbit small intestinal contractions evoked by 
pMTL are directly mediated through motilin receptors on smooth muscle cells, not by the 
intramural nervous system or by muscarinic, nicotinic, histamine or opiate receptors. This 
notion is also supported by receptor binding studies with 125I-labeled motilin (this study; 
Bormans et al., 1986) and by a mechanical study in rabbit colonic myocytes (Hasler et al., 1992). 
In in vivo preparations such as conscious dogs, on the other hand, it seems that motilin also acts 
on enteric neurons to stimulate the gastric and small intestinal motility (Sarna et al., 1983; Fox, 
1990). It remains to be determined whether GM-109 could also be a selective antagonist of 
neural motilin receptors in in vivo experiments.  
In the present study, a single administration (noncumulative) of 10 nM pMTL induced a 
contraction almost equal in magnitude to that elicited by 100 μM ACh in the rabbit duodenal 
tissue preparation, even though the same concentration of pMTL added cumulatively induces 
only 68.9 ± 1.9% (n = 10) of the effect of 100 μM ACh. Although it remains unclear exactly 
how this difference in the contractile response to pMTL arises, the following mechanism 
deserves consideration. In cumulative studies to date, the contraction evoked by subsequently 
applied 10 nM pMTL was superimposed on a stable tension level induced by previously applied 
lower concentrations of pMTL (it consisted mainly of a tonic response). As a consequence, the 
amplitude of contraction evoked by cumulative application of pMTL may have been smaller 
than that observed after a single administration. Satoh et al. (1990) and Kitazawa et al. (1994), 
for instance, have in fact reported that the amplitude of contraction evoked by a single 
administration of 10 μM pMTL is higher than that induced by the same concentration of pMTL 
applied cumulatively in the isolated rabbit small intestine.  
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Ōmura et al. (1987) and Satoh et al. (1990) found that rhythmic spontaneous contractions of the 
isolated rabbit small intestine were markedly diminished, and were accompanied by a decrease 
in resting tone, by the removal of calcium from the media or by exposure to atropine or 
verapamil, a calcium entry blocker (Godfraind et al., 1986). In the present experiment, however, 
the selective motilin antagonist GM-109 did not affect the spontaneous movement or resting 
tone of rabbit duodenal strips, even at concentrations sufficient to inhibit pMTL-evoked 
contractions. These findings suggest that the spontaneous movement and resting tone of the 
isolated rabbit small intestine depend largely on extracellular calcium and ACh, which is 
spontaneously released from the small intestine, but do not depend on motilin. Thus, it is likely 
that in the isolated small intestine, motilin is not released spontaneously under resting conditions.  
According to previous reports by Itoh et al. (1976) and Vantrappen et al. (1979), in conscious 
dogs and humans, exogenous motilin induces a premature MMC cycle and the occurrence of 
MMCs in the upper small intestine is associated with peaks in the plasma level of motilin, which 
suggests that the plasma motilin cycle is the cause of initiation of the MMC in the upper 
gastrointestinal tract. Sarna et al. (1983) and Sarna (1985), on the other hand, have suggested 
that motilin is released mainly by the contractile activity of the duodenum and upper jejunum 
and that endogenous motilin does not initiate the spontaneous MMC in conscious dogs. At the 
present time, it remains unclear what is the cause and what the effect, even though the two 
events are generally temporally associated. Furthermore, several results from in vivo studies 
argue against motilin receptors playing a physiological role in the mechanisms of billiary tract 
MMC-like activity (Svenberg and Nilsson, 1990) and the secretory phase of MMC (Konturek et 
al., 1990). GM-109, a selective motilin receptor antagonist, may prove to be a useful tool for 
exploring the various physiological roles of motilin receptors, but demonstrating this will 
require extensive in vivo experiments. 
In summary, GM-109 behaves as a selective and competitive motilin receptor antagonist in the 
smooth muscle of the rabbit small intestine. It is clear that a selective motilin antagonist such as 
GM-109 should be of considerable value in the further pharmacological and physiological 
characterization of the role(s) of the motilin receptor in gastrointestinal function. 
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1.5 Summary 
The pharmacological properties of the cyclic peptide Phe-cyclo[Lys-Tyr(3-tBu)-βAla-
]·trifluoroacetate (GM-109), a selective motilin antagonist, were investigated in the smooth 
muscle of the rabbit small intestine. GM-109 (0.1-3 µM) competitively inhibited contractions 
induced by pMTL in rabbit isolated duodenum longitudinal strips, with a pA2 value of 7.37 ± 
0.24. However, the contractile response to acetylcholine, to substance P, to prostaglandin F2α, 
and to KCl was unaffected by 10 µM GM-109 in the same preparation. Both GM-109 and 
pMTL competitively inhibited 125I-pMTL binding to motilin receptors in a homogenate of the 
rabbit small intestinal smooth muscle tissue. The pKi value of GM-109 and the pKd value of 
unlabeled pMTL were 7.99 ± 0.04 and 9.25 ± 0.06 (each n = 5), respectively. These results 
indicate that GM-109 is a selective and competitive motilin receptor antagonist in the smooth 
muscle of the rabbit small intestine. Thus this compound may be a useful pharmacological tool 
for examining the functional role(s) of motilin. 
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2. In Vitro Pharmacological Characterization of Mitemcinal in 
Smooth Muscle of Rabbit Small Intestine 
2.1 Introduction 
Many investigators have reported that a macrolide antibiotic, erythromycin A (EMA), exhibits a 
motilin-like effect on the gastrointestinal tract, both in vivo and in in vitro conditions (Itoh, 
1997; Peeters, 2006) via motilin receptors, since EMA can displace 125I-labeled motilin bound to 
the receptor (Peeters et al, 1989; Hasler et al., 1992). Further efforts to eliminate the 
antimicrobial activity as well as enhance the motilin-like activities produced a large number of 
derivatives such as EM-523 (Ōmura et al., 1987), EM-574 (Tsuzuki et al., 1989), ABT-229 (Li 
et al., 2004) and others (Faghih et al., 1998) in the hope of ameliorating the motility disorders in 
patients with idiopathic, diabetic, post-operative or chemotherapy induced gastroparesis. 
Unfortunately, most of EMA derivatives rapidly degrade in acidic pH as in the stomach (Koga 
et al., 1994). 
Mitemcinal ([2S,4R,5R,8R,9S,10S,11R,12R]-9-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-
hexopyranosyl)oxy]-5-ethyl-4-methoxy-2,4,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-
(isopropylmethylamino)-β-D-xylo-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-
14(1)-ene-3,7-dione(E)-2-butenedioic acid salt (2:1)) (Figure 2-1), has been synthesized in an 
attempt to improve acid stability. In this new derivative, internal ketalization of the 12-hydroxy 
group of EMA, which occurs under acidic conditions, is protected by 12-O-methylation, so that 
the acidic stability is greatly increased. Furthermore, small sophisticated modifications in other 
side chains have conferred enhanced motilin activity, making mitemcinal promising as an orally 
administrable prokinetic agent (Koga et al., 1994). 
Accordingly, mitemcinal was created to develop the first acid-resistant non-peptide motilin 
agonist, with high prokinetic activity but devoid of antibacterial activity. We previously reported 
the stability of mitemcinal by comparing it with that of EM-523 under several pH conditions at 
37°C by means of HPLC. EM-523 was immediately and almost completely degraded within 15 
min below pH 3.0, while mitemcinal was slowly degraded and remained unchanged form 
approximately 40% in pH 2.2 even after 6 hours (Koga et al., 1994). Mitemcinal has been also 
shown to improve the delayed gastric emptying in patients with idiopathic and diabetic 
gastroparesis (Fang et al., 2004; Kipnes et al., 2004). 
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In the present study, we therefore investigated the pharmacological profiles of mitemcinal-
induced effects on the small intestine isolated from rabbits and compared these effects with 
those of porcine motilin (pMTL), EMA, and its derivatives (EM-523, EM-574, and ABT-229). 
Furthermore, we also evaluated the acid-resistant property of mitemcinal by comparing it with 
those of other EMA derivatives from the view point of pharmacological motilin activity. 
 
Figure 2-1  Chemical structure of erythromycin A (EMA, molecular weight is 
733.93) (A) and mitemcinal (molecular weight is 814.02) (B). The chemical 
structural differences of mitemcinal from that of EMA are surrounded by circles. 
 
2.2 Materials and methods 
2.2.1 Animals 
Male Japanese-White rabbits/CSK (approx. 2-3 kg; Chugai Research Institute for Medical 
Science, Inc., Shizuoka, Japan) were used. All animal procedures were conducted in accordance 
with Chugai Pharmaceutical's ethical guidelines for animal care, and all experimental protocols 
were approved by the Animal Care Committee of the institution. 
 
2.2.2 Procedures for recording contractile activity 
The animals were anesthetized with thiopental sodium (30 mg/kg, i.v., Ravonal®, Tanabe 
Seiyaku, Osaka, Japan) and exsanguinated. The upper part of the small intestine was rapidly 
removed after laparotomy and placed in an ice-cold modified Krebs’ solution composed of (in 
mM): NaCl 120.0, KCl 4.7, CaCl2 2.4, KH2PO4 1.0, MgSO4 1.2, NaHCO3 24.5, and glucose 5.6 
(pH 7.4). The duodenum was washed, freed from mesenteric attachment and cut along the 
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longitudinal axis to obtain muscle strips approximately 10 mm long and 3 mm wide. The 
preparation was mounted in an organ bath containing 10 ml of modified Krebs’ solution kept at 
28°C to prevent excessive spontaneous contractions (Adachi et al., 1981). The solution was 
gassed with a mixture of 95% O2 and 5% CO2. The longitudinal strips were initially loaded with 
a 1.0 g weight, and contractile activity was measured by means of isotonic transducers (ME-
4012, Medical Electronics Co., Tokyo, Japan) and recorded on an ink-writing recorder (Type 
3066, Yokogawa-Denki, Tokyo, Japan). Before the experiments, each strip was subjected to 
repeated stimulation with 100 μM acetylcholine (ACh) until a reproducible response was 
obtained. In isolated rabbit small intestinal muscle strips, contractions induced by EMA and its 
derivatives as well as pMTL consisted of tonic contractions (basal tone of the muscle) and 
phasic contractions (oscillatory components) (Yamada et al., 1996) (Figure 2-2A and B). 
Therefore, mitemcinal, pMTL, EMA, EM-523, EM-574, or ABT-229 was added cumulatively 
to the organ bath, and the contractile potency of each agonist on tonic contractions was 
expressed as a percentage of that induced by 100 μM ACh in order to normalize the data in the 
present experiment. All drug concentrations are expressed as final molar (M) concentrations in 
the bath solution. The concentration at which contraction was 50% of the maximal contraction 
due to ACh was determined by two-point interpolation, and this value represented as EC50 value. 
 
2.2.3 Pharmacological analysis of the contractile mechanism of mitemcinal 
Isolated duodenum preparations were treated for 15 min with either of atropine (1 μM), 
tetrodotoxin (TTX, 1 μM), hexamethonium (1 μM), naloxone (10 μM), tropisetron (1 μM), or 
GM-109 (0.1-3 μM) before mitemcinal or pMTL was added to the organ bath. The cumulative 
concentration-response curve in the absence or presence of each blocker was compared and the 
EC50 value calculated. Effective concentrations of atropine, TTX (Adachi et al., 1981), 
hexamethonium (Xie et al., 2003), naloxone (Su et al., 1998), tropisetron (antagonistic effects to 
5-HT3 and 5-HT4 receptors) (Craig and Clarke, 1990), and GM-109 (Figure 1-1, selective 
antagonist effects to motilin receptors) (Takanashi et al., 1995) in isolated intestine as described 
in the literature were used. In the study treated with GM-109, the pA2 value (-log value of the 
antagonist concentration required to move the agonist concentration-response curve twofold 
towards the higher concentration side) and slope were obtained by regression analysis of Schild 
plots as has been described previously (Arunlakshana and Schild, 1959). 
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In other experiments, the role of extracellular Ca2+ in the contractile action of mitemcinal or 
pMTL was studied. Namely, the contraction by mitemcinal or pMTL was observed first, then the 
effects of pretreatment of verapamil (1 μM) for 30 min or changing the medium to a Ca2+-free 
solution (containing 1 mM EGTA) for 30 min on the contraction induced by mitemcinal or 
pMTL was investigated. In the experiment using verapamil, the EC30 value was calculated. 
 
2.2.4 Acid-resistant property of mitemcinal 
Contractile responses of mitemcinal (30 nM), EM-523 (100 nM), EM-574 (30 nM), and ABT-
229 (10 nM) preincubated with saline at 37°C, the pH of which was adjusted to 7.40 (control), 
4.30, 2.75, or 1.20 by hydrochloric acid, were examined. 
 
2.2.5 Motilin receptor binding assay procedures 
Binding assay for the motilin receptor was performed according to the procedure introduced by 
Bormans et al. (1986) with a slight modification. After exsanguination, the upper part of the 
small intestine (about 50 cm) of the rabbit was rapidly removed and rinsed with ice-cold 0.9% 
saline. The smooth muscle tissue was dissected free from connective tissue and mucosa, finely 
minced and homogenized in 50 mM Tris-HCl buffer (pH 7.4) at 0°C using tapered tissue 
grinders (Wheaton, Miliville, NJ) for 30 sec. The homogenate was centrifuged (Hitachi Koki 
Co., Ltd, TMP-22, Tokyo, Japan) at 1,500 g for 5 min and was washed twice with a fresh buffer.  
The final pellet was resuspended in 50 ml of 50 mM Tris-HCl buffer (pH 8.0, containing 10 mM 
MgCl2 and 1.5% bovine serum albumin) for binding studies. The protein concentration was 
determined by the method of Lowry et al. (1951) using bovine serum albumin as the standard. 
The homogenate (approx. 1.0 mg protein/assay) was incubated at 25°C for 120 min with 25 pM 
125I-pMTL (the final volume was 1 ml). After incubation, the reaction was stopped by adding 2 
ml of ice-cold buffer. Bound and free reagents were separated by centrifugation at 1,500 g for 5 
min. The pellet was washed with an ice-cold buffer, and its radioactivity was determined with a 
gamma counter (ARC-300, Aloka, Tokyo, Japan). Specific binding was defined as the difference 
between total binding and nonspecific binding determined after the addition of 1 μM pMTL. 
Displacement curves were obtained by adding increasing amounts of mitemcinal, unlabeled 
pMTL, EMA, EM-523, EM-574, or ABT-229 to the incubation sample and the concentrations 
reducing specific binding by 50% (IC50) were determined. 
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From experiments with unlabeled pMTL, its dissociation constant (Kd) was calculated by 
Scatchard analysis. And from experiments with other compounds, its dissociation constant (Ki) 
was calculated as follows: Ki = IC50/(1+[L]/Kd), where [L] is the concentration of labeled pMTL. 
Hill coefficient values were also calculated by a logistic equation (Hill, 1910). 
 
2.2.6 Affinities of mitemcinal on various receptors, ion channels and 
enzymes 
The affinities of mitemcinal to various receptors and ion channels, and its actions on enzymes 
were examined at Cerep (Celle l'Evescault, Poitiers, France) and MDS Panlabs (Panlabs-Taiwan, 
Ltd, Taipei, Taiwan). For each radioligand binding assay to receptors and ion channels, as listed 
in Table 1, target tissue, cell line, or recombinant receptor and radioligand were used. The 
specific binding inhibition was determined as percent inhibition. The substrate used and the 
reactions observed were also listed in Table 2-4. Enzyme inhibition was determined as percent 
inhibition of conversion of substrate or phosphorylation of substrate. 
 
2.2.7 Drugs  
Mitemcinal, GM-109, EM-523, EM-574, ABT-229, and tropisetron (ICS-205-930) were 
synthesized in our organic chemistry laboratory. Other compounds and their sources were pMTL, 
atropine sulfate, TTX, hexamethonium chloride, naloxone hydrochloride, and verapamil 
hydrochloride (Sigma Chemical Co., St. Louis, MO), EMA (Aldrich Chemical Co., Inc., 
Milwaukee, WI), ACh chloride (Daiichi Pharmaceutical Co., Tokyo, Japan), and 125I-pMTL 
(Peninsula Laboratories Inc., Belmont, CA).  Mitemcinal, EMA, EM-523, EM-574, ABT-229, 
and tropisetron were first dissolved in dimethyl sulfoxide (DMSO) and then diluted with 0.9% 
saline or distilled water. Other drugs were dissolved in 0.9% saline or distilled water (only TTX 
required the pH to be adjusted to 4-5 with acetic acid before dissolving). 
 
2.2.8 Statistical analysis 
Data are expressed as mean ± SEM. Statistical analysis was performed by Dunnett’s multiple 
comparison test, Student’s t test or paired t test. P values less than 0.05 were considered 
statistically significant. 
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2.3 Results 
2.3.1 Contractile activities of mitemcinal and other motilin agonists 
The isolated rabbit longitudinal duodenal muscle strips showed a rhythmic spontaneous 
contraction superimposed on the base-line tonus and adding DMSO to the organ bath (final 
percentage, 0.2 v/v%) did not cause any changes in the contractile activity. The contractions 
induced by increasing concentrations of mitemcinal or pMTL are shown in Figure 2-2A and B.  
Mitemcinal (1-300 nM), EMA (10-10,000 nM), EM-523 (1-300 nM), EM-574 (1-300 nM), or 
ABT-229 (1-300 nM) produced similar concentration-dependent contractions of the isolated 
duodenal strips as well as pMTL (0.1-100 nM) (Figure 2-2C and D). The EC50 values and 
maximum contractions of duodenal strips (% of 100 μM ACh) for all compounds tested are 
shown in Table 2-1, respectively. 
 
Table 2-1  EC50 values and the maximal contraction induced by mitemcinal, pMTL, 
EMA, EM-523, EM-574, and ABT-229 in isolated rabbit longitudinal duodenal 
muscle strips. 
 EC50 Value Maximal Contraction 
 Agonists (n) (nM) (% of 100 μM ACh) 
 Mitemcinal (6) 14.80 ± 2.55 94.3 ± 8.5 
 pMTL (10) 4.33 ± 0.43 101.3 ± 5.2 
 EMA (9) 1260 ± 230 99.7 ± 3.9 
 EM-523 (12) 17.03 ± 2.56 93.8 ± 3.7 
 EM-574 (9) 8.11 ± 0.89 103.3 ± 4.9 
 ABT-229 (6) 6.71 ± 2.05 97.9 ± 6.8 
Each value represents the mean ± SEM. 
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Figure 2-2  Typical tracing of contractions of rabbit duodenal strips induced by 
cumulative application of mitemcinal (A) and pMTL (B). Numbers show the molar 
concentration of each drug in the organ bath. Horizontal bar shows 10 min. 
Concentration-response curves for mitemcinal- (○) and pMTL- induced (∆) 
contractions in the isolated duodenal strips (C). Concentration-response curves 
for pMTL- (∆), EMA- (□), EM-523- (●) EM-574- (▲), and ABT-229-induced (■) 
contractions in the isolated duodenal strips (D). The ordinate scale represents 
the percent of the contraction induced by 100 μM ACh.  Each point represents 
the mean ± SEM from 6-12 preparations. 
 
2.3.2 Effects of antagonists and Ca2+ removal from the medium on 
mitemcinal- or pMTL-induced contraction 
Pretreatment of GM-109 (0.1 - 3 μM) for 15 min, which had no effect on the resting tone or 
spontaneous contractions, induced a parallel rightward shift in the concentration-dependent 
contractile response curves for mitemcinal and pMTL without significantly reducing these 
maximal contractile responses (Figure 2-3A and B). The pA2 values calculated by Schild 
analysis for GM-109 as an antagonist of mitemcinal and pMTL were 7.38 ± 0.10 (slope, 1.13 ± 
0.09) and 7.31 ± 0.12 (slope, 0.99 ± 0.10), respectively (Figure 2-3C and D).   
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Figure 2-3  Concentration-response curves for mitemcinal- (A) and pMTL-induced 
(B) contractions in the isolated duodenal strips in the absence (○) or presence of 
GM-109 (∆, 0.1 μM; □, 0.3  μM ; ●, 1 μM ; ▲, 3 μM ). The ordinate scale represents 
the percent of the contraction induced by 100 μM ACh. Each point represents the 
mean ± SEM from 6-10 preparations. Schild analysis of antagonism by GM-109 of 
mitemcinal- (C) and pMTL-induced (D) contractions in rabbit isolated duodenal 
strips. The pA2 values for GM-109 as an antagonist of mitemcinal and pMTL are 
7.38 ± 0.10 (slope 1.13 ± 0.09) and 7.31 ± 0.12 (slope 0.99 ± 0.10), respectively. 
 
As shown in Figure 2-4, however, the concentration-dependent contractile responses of rabbit 
duodenal strips to mitemcinal and pMTL were not affected by pretreatment with atropine (1 
μM), TTX (1 μM), hexamethonium (1 μM), naloxone (10 μM), or tropisetron (1 μM).  
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Figure 2-4  Concentration-response curves for mitemcinal- and pMTL-induced 
contractions in the isolated duodenal strips in the absence (○, mitemcinal; ∆, 
pMTL) or presence (●, mitemcinal; ▲, pMTL) of 1 μM of atropine (A), 1 μM of TTX 
(B), 1 μM of hexamethonium (C), 10 μM of naloxone (D), or 1 μM of tropisetron (E). 
The ordinate scale represents the percent of the contraction induced by 100 μM 
ACh.  Each point represents the mean ± SEM from 6-9 preparations. 
 
Adding verapamil (1 μM) to the organ bath markedly diminished the rhythmic contractions of 
the duodenal strips and slightly decreased the basal tonus. The concentration-response curves 
for mitemcinal and pMTL were shifted to the right and maximal contractions were diminished 
by the treatment of the preparations for 30 min with 1 μM verapamil (Figure 2-5A). The EC30 
values (% of the contraction induced by 100 μM ACh) of duodenal strips for mitemcinal and 
pMTL were calculated, since not all preparations reached 50% of the contraction induced by 
100 μM ACh after verapamil. As shown in Table 2-2, The EC30 values and maximal 
contractions (% of 100 μM ACh) by mitemcinal and pMTL in isolated duodenal strips showed 
the significant difference when comparing them in the absence and presence of verapamil. After 
changing the medium to a Ca2+-free solution, the preparations relaxed and the spontaneous 
movement disappeared. Under these conditions, the contractile responses to 30 nM of 
mitemcinal or 10 nM of pMTL were completely abolished, respectively (Figure 2-5B and C).  
Adding 2.4 mM CaCl2 to the Ca2+-free medium in the presence of mitemcinal or pMTL 
recovered contractions (Figure 2-5B and C). 
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Figure 2-5  Concentration-response curves for mitemcinal- and pMTL-induced 
contractions in isolated duodenal strips in the absence (○, mitemcinal; ∆, pMTL) 
or presence (●, mitemcinal; ▲, pMTL) of verapamil (1 μM) (A). The ordinate scale 
represents the percent of the contraction induced by 100 μM ACh. Each point 
represents the mean ± SEM from 3 or 8 preparations. Typical tracings of 
contractions of rabbit duodenal strips induced by application of 30 nM of 
mitemcinal (B) and 10 nM of pMTL (C) in Ca2+ free medium. Numbers show the 
molar concentration of each drug in the organ bath. Horizontal bar shows 10 min. 
 
Table 2-2  Effect of verapamil (10 μM) on the EC30 values and the maximal 
contraction induced by mitemcinal and pMTL in isolated rabbit longitudinal 
duodenal muscle strips. 
 EC30 Value Maximal Contraction 
 (nM) (% of 100 μM ACh) 
 Agonists Control (n) After verapamil (n) Control (n) After verapamil (n) 
 Mitemcinal 6.72 ± 1.16 (3)  47.49 ± 15.37* (8) 105.3 ± 5.7 (3) 41.9 ± 7.0* (8) 
 pMTL 1.36 ± 0.09 (3) 33.71 ± 21.56* (8) 102.9 ± 1.7 (3) 53.3 ± 6.8* (8) 
Each value represents the mean ± SEM.  *P<0.05 compared with the control group by Student’s 
t test. 
 
2.3.3 Acid-resistant profile of motilin agonists 
After 30-min preincubation in 0.9% saline adjusted to pH 7.40 (control), the contractions 
induced by mitemcinal (30 nM), EM-523 (100 nM), EM-574 (30 nM), and ABT-229 (10 nM) 
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were 88.0 ± 6.25%, 93.2 ± 5.50%, 105.1 ± 3.39%, and 84.4 ± 5.79% (% of the contraction 
caused by 100 μM ACh, each n=8), respectively. The contractile responses to mitemcinal 
preincubated in solutions adjusted to 4.30, 2.75, and 1.20 were 94.8% ± 5.72%, 89.4 ± 5.28%, 
and 86.0 ± 7.63% (each n=8), respectively, of that caused by 100 μM ACh (Figure 2-6). 
However, the contractile responses of EM-523, EM-574, and ABT-229 under pH conditions of 
2.75 and 1.20 were significantly decreased compared to each control. In particular, almost no 
contractions (% of 100 μM ACh) of EM-523 (7.4 ± 2.95%), EM-574 (4.5 ± 1.77%), and ABT-
229 (0.1 ± 0.11%) (each n=8) were observed at pH 1.20 (Figure 2-6). 
 
 
Figure 2-6  Contractile responses of mitemcinal (30 nM), EM-523 (100 nM), EM-
574 (30 nM), and ABT-229 (10 nM) preincubated with 0.9% saline for 30 min at 
37°C, the pH of which was adjusted to 7.40 (Control), 4.30, 2.75, or 1.20, in rabbit 
duodenal strips. The ordinate scale represents the percent of the contraction 
induced by 100 μM ACh. Each column represents the mean ± SEM from 4 or 8 
preparations. * P < 0.05, compared with the corresponding control group by 
Dunnett’s test. 
 
2.3.4 Motilin receptor binding assay 
All of unlabeled pMTL, mitemcinal, EMA, EM-523, EM-574, and ABT-229 displaced 125I-
pMTL bound to the homogenate of the smooth muscle of the rabbit small intestine in a 
concentration-dependent manner (Figure 2-7A and B).The pKd, pKi, and Hill coefficient values 
of mitemcinal, pMTL, EMA, EM-523, EM-574, and ABT-229 are shown in Table 2-3, 
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respectively. Each Hill coefficient value of each motilin agonist was not significantly different 
from unity by Student’s t test. 
To determine whether mitemcinal interacts competitively with motilin receptor, Scatchard 
analysis (Scatchard, 1949) of motilin binding in the presence or absence of mitemcinal was 
carried out. As shown in Figure 2-7C, the presence of mitemcinal (3 nM) increased the Kd value 
of pMTL (control, 0.83 ± 0.16 nM; presence of mitemcinal, 1.47 ± 0.23 nM; P < 0.005 by 
paired t-test; each n = 5) with no significant influence on the maximal binding capacity (Bmax) 
(control, 62.9 ± 7.1 fmol/mg protein; presence of mitemcinal, 67.1 ± 10.6 fmol/mg protein; 
P=0.754 by paired t test; each n = 5). This result indicates that mitemcinal is a competitive 
ligand of motilin to the motilin receptor. 
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Figure 2-7  Displacement of 125I-pMTL binding on the rabbit small intestinal tissue 
by mitemcinal (○) and unlabeled pMTL (∆) (A). Each point represents the mean ± 
SEM from 5 experiments. Displacement of 125I-pMTL binding on the rabbit small 
intestinal tissue by unlabeled pMTL (∆), EMA (□), EM-523 (●), EM-574 (▲), and 
ABT-229 (■) (B). Each point represents the mean ± SEM from 3-5 experiments. 
Scatchard analysis of specific 125I-pMTL binding in the rabbit small intestinal 
tissue in the absence (○) and presence (●) of mitemcinal at 3 nM (C). This is a 
typical experiment and was repeated 5 times with similar results. 
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Table 2-3  pKd, pKi, and Hill coefficient values of mitemcinal, pMTL, EMA, EM-523, 
EM-574, and ABT-229 in the binding studies with using the rabbit small intestinal 
tissue. 
 Agonists (n) pKd Value pKi Value Hill Coefficient Value 
 Mitemcinal (5) - 8.35 ± 0.08 0.95 ± 0.08 
 pMTL (5) 9.11 ± 0.07 - 0.97 ± 0.11 
 EMA (3) - 7.37 ± 0.18 0.88 ± 0.11 
 EM-523 (5) - 8.31 ± 0.16 0.93 ± 0.16 
 EM-574 (3) - 8.46 ± 0.18 0.93 ± 0.16 
 ABT-229 (4) - 8.84 ± 0.10 0.81 ± 0.13 
Each value represents the mean ± SEM. 
 
2.3.5 Affinities of mitemcinal on various receptors, enzymes and ion 
channels 
The effects of mitemcinal at 10 μM on various receptors, ion channels and enzymes are listed in 
Table 2-4. Even at 10 μM, the inhibitory effect of mitemcinal on the receptor and the ion 
channel binding did not reach 50% except for L-type Ca channel (diltiazem site).  Mitemcinal 
also showed no significant inhibition on enzymes activities listed in Table 2-4. Even though 
mitemcinal inhibited the [3H]diltiazem binding in the rat cerebral cortex by 64.1% at 10 μM, 
this concentration was approximately 1,000 times higher than that to inhibit 125I-pMTL binding 
in the smooth muscle of the rabbit small intestine (Table 2-4 and Figure 2-7A). The previous 
report [13] demonstrated that 10 μM of mitemcinal was high enough to strongly inhibit L-type 
Ca channel current in the rabbit duodenum, whereas a wide range concentration of mitemcinal 
(0.1-100 nM) could not enhance L-type Ca channel directly in the same preparation. 
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Table 2-4  Effects of 10 mM mitemcinal on radioligand binding and on inhibition of 
enzyme activity. 
 Receptor Ligand Source Inhibition% 
 Adrenergic α1, Non-selective [3H]Prazosin rat brain 11 
 Adrenergic α2, Non-selective [3H]Rauwolscine  rat brain 2 
 Adrenergic β1 [3H]CGP-12177  human recombinant 10 
 Adrenergic β2 [3H]CGP-12177  human recombinant 17 
 Adrenergic β3 [125I]Cyanopindolol human recombinant 17 
 Muscarinic M1 [3H] N-Methylscopolamine human recombinant -18 
 Muscarinic M2 [3H]N-Methylscopolamine human recombinant -6 
 Muscarinic M3 [3H]N-Methylscopolamine human recombinant 6 
 Nicotinic [3H]Cytisine rat cerebral cortex -16 
 Adenosine A1 [3H]CCPA rat cerebral cortex  -5.3 
 Adenosine A2 [3H]CGS21680 rat striatum  -4.1 
 Serotonin 5-HT1 [3H]Serotonin (5-HT) rat cerebral cortex 4 
 Serotonin 5-HT2 [3H]Ketanserin rat brain -6 
 Serotonin 5-HT3 [3H]GR-65630 rabbit ileum muscularis 20 
 Serotonin 5-HT4 [3H]GR-113808 guinea pig striatum - 
 Histamine H1 [3H]Pyrilamine guinea pig lung 11 
 Histamine H2 [125I]NH2-potentidine guinea pig stratum 10 
 Histamine H3 [3H]NAMH rat brain 22 
 Dopamine D1 [3H]SCH 23390 rat striatum -5.2 
 Dopamine D2 [3H]YM-09151-2 rat striatum 0.8 
 Opiate δ [3H]DPDPE guinea pig brain 6 
 Opiate κ [3H]U-69593 guinea pig brain 3 
 Opiate μ [3H]DAMGO guinea pig brain -10 
 Bombesin [125I]Tyr4-bombesin rat brain 19 
 Calcitonin gene-related peptide [125I]CGRP rat brain 2 
 Cholecystokinin CCK-A [3H]Devazepide rat pancreas -14 
 Cholecystokinin CCK-B [3H]CCK-8 guinea pig brain 21 
 Neurokinin NK1 [3H]Substance P guinea pig submaxillary gland 19 
 Somatostatin [125I]Tyr11-SS-14 mouse AtT-20 cells 10 
 Vasoactive intestinal peptide [125I]VIP guinea pig lung -14 
 Inositol 1,4,5-triphosphate [3H](1,4,5)IP3 rat cerebellum 10 
 Channel Ligand Source Inhibition% 
 Ca channel L, DHP site [3H]PN 200-110 rat cerebral cortex  -8.6 
 Ca channel L diltiazem site [3H]diltiazem rat cerebral cortex  64.1 
 Ca channel L, verapamil site [3H]D 888 rat cerebral cortex  -20.2 
 Ca channel N-type [125I]ω-conotoxin GVIA rat cerebral cortex  -3.3 
 K channel ATP-sensitive [3H]glibenclamide rat cerebral cortex -4.6 
 K channel Volt-dependent [125I]charybdotoxin rat cerebral cortex 4.4 
 K channel Ca-dependent [125I]apamin rat cerebral cortex -8.8 
 Enzyme Substrate, Reaction Source Inhibition% 
 Acetylcholinesterase Acetylthiocholine→ Acetate + Thiocholine human  erythrocytes 4 
 Phospholipase A2 [14C]3-Phosphatidylcholine→ Palmitate porcine  pancreas 5 
 Protein kinase C Hisiton H1 (HH1)+[γ-32P]ATP→ [32P]HH1 + ADP rat brain 2 
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2.4 Discussion 
The findings in the present contractile study show that mitemcinal acts as a selective and full 
motilin receptor agonist in the rabbit small intestine with an excellent acid-resistant property. 
The fact that mitemcinal interacts selectively with the motilin receptor was also confirmed by 
the present binding study. 
In the present contraction experiments, mitemcinal, similar to motilin as well as EMA and its 
derivatives (EM-523, EM-574, and ABT-229), caused a concentration-dependent contraction of 
rabbit isolated duodenal longitudinal muscle strips. The concentration-dependent contraction 
curves for all compounds were parallel with approximately the same maximum contractions.  
The EC50 values of mitemcinal and pMTL in the present study were 14.33 ± 2.55 nM (n=6) and 
4.33 ± 0.43 nM (n=10). The result is consistent with the previous report (Yamada et al., 1996) 
that both of mitemcinal and pMTL induced the dose-dependent tonic contraction in the rabbit 
duodenal muscle strip with EC50 values 11.9 nM for mitemcinal and 3.0 nM for pMTL, 
respectively. The selective motilin antagonist, GM-109, shifted the concentration-dependent 
curves for mitemcinal and pMTL right in a concentration-dependent manner. Our previous 
study (Takanashi et al., 1995) clearly demonstrated that GM-109 is a selective and competitive 
motilin antagonist at the receptor site in the rabbit small intestine. The pA2 values for GM-109 
as an antagonist of mitemcinal and pMTL were almost equal (7.38 ± 0.10 for mitemcinal and 
7.31 ± 0.12 for pMTL, respectively) in this study. These results indicate that mitemcinal, like 
pMTL, exerts a direct effect on the rabbit small intestine as a motilin receptor agonist. 
On the other hand, the concentration-dependent contractile response to mitemcinal or pMTL 
was not affected by pretreatment with atropine (muscarinic blockade), TTX (axonal conduction 
blockade), hexamethonium (nicotinic blockade), naloxone (opiate blockade), or tropisetron (5-
HT3 and 5-HT4 blockade). This also indicates that the action of mitemcinal, as well as motilin, is 
not mediated by neural activities but by directly mediated effects on intestinal smooth muscle 
motilin receptors in rabbits. These findings are consistent with previous reports (Adachi et al., 
1981; Yamada et al., 1996; Satoh et al., 1990; Sato et al., 1997) in which, by experiments in the 
isolated rabbit small intestine, the contractile response to pMTL or some EMA derivatives was 
found not to be affected by TTX, atropine, hexamethonium, mepyramine (H1 blockade), 
naloxone or CP-99994 (NK1 blockade). These results suggested that contractions evoked by 
pMTL or EMA derivatives in the isolated rabbit small intestine are directly mediated through 
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motilin receptors on smooth muscle cells, not by the intramural nervous system or by 
muscarinic, nicotinic, histamine, opiate, or neurokinin receptors. 
It is well known that the contraction induced by pMTL in the isolated rabbit small intestine is 
strongly dependent on extracellular Ca2+ (Yamada et al., 1996; Satoh et al., 1990; Sato et al., 
1997; Matthijs et al., 1988). In the present study, contractile responses to mitemcinal and pMTL 
were markedly diminished by pre-treatment with verapamil, which blocks the voltage-
dependent L-type Ca channel, or by removing Ca2+ from the medium. This confirms that 
increased Ca2+ influx through the voltage-dependent Ca channel plays a major role in these 
contractions. These results are consistent with a previous report (Yamada et al., 1996) of an 
electrophysiological experiment in the isolated rabbit duodenum that showed that Ca2+ entry 
played a major role in the generation of tonic contractions by mitemcinal or pMTL when it 
occurred via a voltage-dependent pathway as a result of membrane depolarization, but not when 
it occurred via a voltage-independent pathway. In the present study, neither mitemcinal (30 nM) 
nor pMTL (10 nM) could induce any contractile effect in Ca2+-free medium. After verapamil 
pretreatment, on the other hand, the same concentrations of mitemcinal and pMTL were able to 
induce small contractions (30.8 ± 6.64% and 22.7 ± 5.45% of the contraction induced by 100 
mM ACh were induced by mitemcinal and pMTL, respectively, both n=8). Under the above 
conditions, Ca2+ release from the intracellular store may be important. It has been suggested that 
the motilin receptor binds to G-protein (Depoortere et al., 1995) and that mitemcinal and pMTL 
may release Ca2+ from the intracellular store in rabbit duodenal smooth muscle cells via 
generation of IP3 (Yamada et al., 1996). However, it seems that intracellular Ca2+ stores are 
rapidly depleted in gastrointestinal smooth muscle cells, compared to airway and venous smooth 
muscle cells (Casteels and Raeymaekers, 1979; Bond et al., 1984; Baba et al., 1985). In Ca2+-
free medium, intracellular Ca2+ stores may have already been depleted when mitemcinal or 
pMTL was added to the organ bath. Matthijs et al. (1988) reported similar results, that is, that 
the contractile response of rabbit duodenum to pMTL was completely suppressed when Ca2+ 
was removed from the medium. The contraction induced by pMTL in the same preparation was 
not completely suppressed after pretreatment with verapamil (0.03-10 mM), however. Further 
investigations of the roles of extracellular and intracellular Ca2+ on gastrointestinal contractile 
activities induced by motilin agonistic agents are desirable. 
The fact that the contractile response to mitemcinal is mediated directly through motilin 
receptors on smooth muscle cells is also supported by the present receptor binding studies with 
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125I-labeled pMTL. Mitemcinal as well as other motilin agonists displaced 125I-pMTL bound to a 
homogenate of the rabbit intestinal muscle tissue. The displacement curves of all these 
compounds tested were parallel. The Hill coefficient value of mitemcinal was 0.95 ± 0.08 (n=5), 
which indicates that there is no major cooperation of the binding of mitemcinal.  Furthermore, 
from the Scatchard analysis of motilin binding in the presence or absence of mitemcinal, the 
presence of mitemcinal (3 nM) significantly increased the Kd value of pMTL with no significant 
influence on Bmax. This result also indicates that mitemcinal is a competitive ligand of motilin to 
the motilin receptor in the rabbit small intestine. In contrast to the motilin receptor, mitemcinal 
at 10 μM had no affinity to the specific radio labeled binding to the different receptors, enzymes 
and ion channels sites studied in the present study. The results also support of selectivity to the 
motilin receptor of mitemcinal. 
There have been extensive reports in the literature that EMA improves impaired gastric 
emptying in patients with severe diabetic gastroparesis (Janssens et al., 1990), postvagotomy 
gastroparesis (Xynos and Mantides, 1992), idiopathic gastroparesis (Richards et al., 1993) and 
gastroparesis after cancer chemotherapy (Maliakkal et al., 1991). In addition, EMA accelerates 
gastric emptying in normal subjects (Sturm et al., 1996). Thus, prokinetic activity of EMA may 
be useful for the treatment of gastrointestinal disorders. However, EMA itself may disrupt the 
intestinal bacterial flora and induce resistance in bacterial strains due to its antibacterial activity. 
For this reason, EMA derivatives with potent gastrointestinal motor-stimulating activity and no 
antibacterial activity are promising candidates as prokinetic agents. However, the contractile 
responses to EM-523, EM-574, and ABT-229, which were EMA derivatives produced by the 
above efforts, were significantly abolished after treating in an acidic solution. In contrast, the 
contractile response to mitemcinal was not affected even when treated in an acidic solution of 
pH 1.20, as in the stomach. The present findings demonstrate that mitemcinal has an excellent 
acid-resistant property from even the pharmacological motilin agonistic activity, which is 
consistent with the results by Koga et al. (1994) that the stability of mitemcinal was greatly 
increased even in an acidic condition while EM-523 rapidly degraded in the acidic solution. 
Mitemcinal seems to be of great advantage when administered orally because of such profiles. 
Delayed gastric emptying is often considered being an important pathophysiological mechanism 
for symptom generation in gastroparesis (Feldman and Schiller, 1983) and functional dyspepsia 
(Talley, 1995). In particular, symptoms of nausea, vomiting, early satiety and bloating are 
attributed to delayed or abnormal gastric emptying. As such, EMA derivatives as prokinetic 
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agents are attempting to be given to treat these symptoms. Because of diminishing motilin 
agonistic activity by rapid degradation of EMA derivatives in acidic condition, oral 
administration of these EMA derivatives were used in an enteric coating formulation in a 
previous clinical study (Verhagen et al., 1997). It is unlikely to make sense that an enteric 
coating formulation is administered to patients with delayed or abnormal gastric emptying. On 
the other hand, the clinical development program of mitemcinal has been investigating the 
safety and effectiveness of an oral simple tablet for the treatment of gastroparesis. In these 
programs, mitemcinal has been shown to improve delayed gastric emptying (Fang et al., 2004; 
Kipnes et al., 2004) and symptoms (McCallum et al., 2005; McCallum and Goldstein, 2006) in 
patients with gastroparesis even after oral administrations. It is considered that the acid-resistant 
property of mitemcinal may play an important contribution to the effectiveness in the above 
clinical studies after oral administration. 
In summary, mitemcinal behaves as a selective and full motilin receptor agonist in the smooth 
muscle of the rabbit small intestine with an acid-resistant property. This profile of mitemcinal 
may be useful in the treatment of gastrointestinal disorders even after oral administration. 
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2.5 Summary 
The pharmacological properties of mitemcinal, the first acid-resistant nonpeptide motilin agonist, 
were investigated in the smooth muscle of the rabbit small intestine and compared with porcine 
motilin (pMTL), erythromycin A (EMA) and its derivatives (EM-523, EM-574, and ABT-229). 
Mitemcinal, pMTL, EMA, EM-523, EM-574, and ABT-229 produced concentration-dependent 
contractions with approximately the same maximum contractions in the isolated rabbit 
duodenum longitudinal strips. The contractile response to mitemcinal or pMTL was 
competitively inhibited by a selective motilin antagonist, GM-109. The pA2 values for GM-109 
as an antagonist of mitemcinal and pMTL showed approximately the same values. However, the 
concentration-dependent contractile responses to mitemcinal or pMTL were not affected by 
pretreatment with atropine, tetrodotoxin, hexamethonium, naloxone, or tropisetron. The removal 
of calcium ions from the medium and pretreatment with verapamil greatly suppressed the 
contractions induced by mitemcinal and pMTL. The contractile response to mitemcinal was not 
affected by preincubation in acidic solutions, while those of EM-523, EM-574, and ABT-229 
were strongly diminished in the same condition. Mitemcinal as well as other motilin agonists 
displaced 125I-pMTL bound to a homogenate of the rabbit duodenum muscle tissue. The 
displacement curves of all these compounds were parallel. These results indicate that 
mitemcinal is a selective and full motilin receptor agonist in the smooth muscle of the rabbit 
small intestine and that this agent has an excellent acid-resistant property. 
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3. Effects of Mitemcinal, an Acid-Resistant Nonpeptide Motilin 
Receptor Agonist, on the Gastrointestinal Contractile Activity in 
Conscious Dogs 
 
3.1 Introduction 
Nearly two decades have passed since it was reported that erythromycin A (EMA), a macrolide 
antibiotic, stimulated gastrointestinal motility and mimicked the effect of motilin in dogs (Itoh 
et a., 1984). In the meantime, it has been demonstrated that EMA binds to motilin receptors in 
rabbits and humans (Peeters et al., 1989; Itoh, 1997) and also stimulates gastrointestinal 
contractile activity in humans (Tomomasa et al., 1986; Annese et al., 1992; Tack et al., 1992). 
Many derivatives with potent motor stimulating activity but no antibacterial activity have 
therefore been synthesized in the hope of ameliorating motility disorders in patients with 
idiopathic, diabetic, post-operative, or chemotherapy-induced gastroparesis (Ōmura et al., 1987; 
Faghih et al., 1998). Since most of these EMA derivatives degrade motilin agonistic activity 
under acidic conditions, such as are found in the stomach (Koga et al., 1994; Takanashi et al., 
2007), preclinical in vivo studies of these EMA derivatives have usually been performed by 
intravenous (i.v.) or intraduodenal (i.d.) administration (Shiba et al., 1995; Tanaka et al., 1998; 
Cowel et al., 2000). Demonstrating the efficacy of EMA derivatives after oral (p.o.) 
administration was considered likely to be difficult because they degrade under acidic 
conditions. 
Mitemcinal ([2S,4R,5R,8R,9S,10S,11R,12R]-9-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-
hexopyranosyl)oxy]-5-ethyl-4-methoxy-2,4,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-
(isopropylmethylamino)-β-D-xylo-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-
14(1)-ene-3,7-dione(E)-2-butenedioic acid salt (2:1))  is also an EMA derivative with no 
antibiotic activity (Koga et al., 1994). An in vitro study has demonstrated that mitemcinal is a 
potent motilin receptor agonist with excellent acid-resistance (Koga et al., 1994; Takanashi et 
al., 2007). This acid-resistance makes p.o. administration possible. Oral administration of 
mitemcinal has been shown to stimulate gastric emptying in patients with gastroparesis (Fang et 
al., 2004; Kipnes et al., 2004). Our previous study also demonstrated that mitemcinal, even at 
1,000 times higher concentration than that to inhibit 125I-pMTL binding to motilin receptors, had 
no affinity to the specific binding sites of other receptors and ion channels (Takanashi et al., 
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2007). This indicates that mitemcinal is selective for motilin receptors, even though it is likely 
that some actions of EMA in the small intestine were not mediated via motilin receptors at 
higher concentrations (Minocha et al., 1991; Furness et al., 1999). 
The present study investigated the effects on the gastrointestinal contractile activity of i.v. and 
p.o. administration of mitemcinal during interdigestive and digestive states in conscious dogs, 
and compared those effects with those of porcine motilin (pMTL) and EMA derivatives (EM-
523 and EM-574). 
 
3.2 Materials and methods 
3.2.1 Preparation of Animals 
A total of 16 Beagle/CSK dogs of either sex (Chugai Research Institute for Medical Science, 
Inc., Shizuoka, Japan) weighing approximately 10 kg were used. Dogs were divided into 3 
groups and following 3 experiments were carried out separately. All animal procedures were 
conducted in accordance with Chugai Pharmaceutical's ethical guidelines for animal care, and 
all experimental protocols were approved by the Animal Care Committee of the institution. 
After overnight fasting, the animal was anesthetized by i.v. injection of pentobarbital (30-35 
mg/kg, Nembutal; Abbott Labs, Chicago, IL), and the following surgical operations were carried 
out under aseptic conditions. Firstly, to enable i.v. injection of the test drugs, one end of a 
silicon tube (602-205; Dow Corning Co., Midland, MI, USA) was inserted into the superior 
vena cava through a branch of the external jugular vein, and the other end of the tube was 
passed under the skin and out between the scapulas, where it was firmly secured. The abdominal 
cavity was then opened after making an incision precisely at the midline, and force transducers 
(F-12IS; Star Medical Co., Ltd., Tokyo, Japan) were sutured onto the serosa of the 
gastrointestinal tract in an orientation that made it possible to measure circular muscle 
contractions (Itoh et al., 1978) at the gastric antrum (3 cm proximal to the pyloric ring), the 
duodenum (3 cm distal from the pyloric ring), and the jejunum (100 cm distal from the ligament 
of Treitz). The lead wires of the force transducers were brought out of the abdominal cavity 
through a small incision in the abdomen, and then passed under the skin and out between the 
scapulas, where there were firmly secured with silk sutures. For p.o. administration of the test 
drugs, a silicon tube was inserted into the stomach by making a small incision at a predefined 
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site on the corpus, and the other end was fixed between the scapulae in the same position as the 
lead wires of the force transducers. The intraperitoneal cavity was sterilized and the abdominal 
wound was closed up. The dog was then placed in a jacket (Takasaki Gishi Co., Ltd., Gunma, 
Japan) to protect the silicon tubes and the lead wires of the force transducers. The dogs were 
used in experiments after a 2-3 week recovery period. 
 
3.2.2 Measurement and Analysis of the Gastrointestinal Contractile Activity 
The gastrointestinal contractile activity was recorded using a thermal pen recorder (WR3701; 
Graphtec Corporation, Tokyo, Japan) by connecting the lead wires of the force transducers to an 
Itoh-type amplifier (SS-1786; Nihon Kohden Co., Tokyo, Japan). To measure the contractile 
activity of the gastric antrum quantitatively, the signal from the gastric antrum was fed into a 
personal computer (PC9801 or PC9821; NEC, Tokyo, Japan). Quantitative analysis was 
performed by calculating the motor index (MI) from the area between the contractile wave and 
the baseline. The gastric antrum MI was evaluated based on the assumption that the contraction 
area is 100 when the maximum contraction of phase III contractions of migrating motor 
complexes (MMCs) lasts for 1 min (Inatomi et al., 1989). In the interdigestive state, the gastric 
antrum MI was used for quantitative analysis. In the digestive state, the gastric antrum MI 
during the 20 min before drug administration was designated as 100% and the percentage 
change in the gastric antrum MI caused by the test drugs was calculated every 20 min. 
 
3.2.3 Experimental Procedure for the Gastrointestinal Contractile Activity 
Firstly, the effects of the test drugs on the gastrointestinal contractile activity in the 
interdigestive state were investigated in 5 conscious dogs. During the interdigestive state, 
mitemcinal (0.3-30 μg/kg), EM-523 (0.3-30 μg/kg), EM574 (0.3-30 μg/kg), or pMTL (0.01-
3μg/kg, i.v. only) was administered i.v. or p.o. 20 min after the termination of phase III MMCs 
in the gastric antrum. Dose-response curves were generated for the effect of each test drug on 
the gastric antrum MI. 
Secondly, the effects of a receptor agonist and various receptor antagonists, including a motilin 
receptor antagonist (GM-109) (Takanashi et al., 1995), on the mitemcinal-induced 
gastrointestinal contractile activity in the interdigestive state were examined in 5 conscious dogs. 
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Dose-response curves for effects on the gastric antrum MI of i.v. injections of mitemcinal or 
pMTL in the presence or absence of continuous i.v. infusion of GM-109 were constructed.  
Intravenous infusion of GM-109 (at 1 or 10 mg/kg/h) was started 10 min after the termination of 
phase III MMCs in the gastric antrum, and then mitemcinal or pMTL was administered i.v. 10 
min after the start of GM-109 infusion. GM-109 infusion was stopped 30 min after the 
administration of mitemcinal or pMTL. The effects of the other receptor agonist and antagonists 
on mitemcinal (3 μg/kg, i.v.)-induced gastric contractions were also examined. As shown in 
Table 1, each dose of each drug was firstly bolus injected i.v. 10 min after the termination of 
phase III MMCs in the gastric antrum, and then continuously infused i.v. for 40 min. 
Mitemcinal was administered i.v. 10 min after the start of the infusion of each drug. The gastric 
antrum MI for 30 min after administration of mitemcinal was calculated. 
Finally, the effects of the test drugs on the gastrointestinal contractile activity during the 
digestive state were investigated in 6 conscious dogs. Mitemcinal (3-100 μg/kg, i.v.; 300-3,000 
μg/kg, p.o.), EM-523 (10-300 μg/kg, i.v.; 3,000-30,000 μg/kg, p.o.), EM574 (3-100 μg/kg, i.v.; 
1,000-10,000 μg/kg, p.o.), pMTL (0.1-3μg/kg, i.v. only), 0.9% saline (the corresponding vehicle 
for the i.v. administrations), or 3% gum arabic solution (the corresponding vehicle for the p.o. 
administrations) was administered 2 hours after feeding. This dosing schedule was chosen 
because the stable digestive pattern of the gastric contractile activity continues for 
approximately 1 to 5 hours after feeding. The gastrointestinal contractile activity in each dog 
was recorded over a 120-min period after the administration of each test drug. In addition, the 
integrated gastric antrum MI up to 20, 60, and 120 min after administration of each test drug 
were calculated and expressed MI0-20min, MI0-60min, and MI0-120min, respectively, to compare the 
efficacy of each test drug. 
 
3.2.4 Drugs 
Mitemcinal, GM-109, EM-523, and EM-574 were synthesized in our organic chemistry 
laboratory. Other compounds and their sources were pMTL, atropine sulfate, hexamethonium 
chloride, phentolamine hydrochloride, propranolol hydrochloride, dopamine hydrochloride 
(Sigma Aldrich Co., MI, USA), ondansetron hydrochloride (GlaxoSmithKline Japan, Tokyo, 
Japan), and ketanserin tartrate (Tocris Cookson Inc., MI, USA). For i.v. administration, 
ketanserin tartrate was dissolved in sterilized water and then diluted with 0.9% saline. The other 
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compounds were dissolved and diluted with 0.9% saline. For p.o. administration, mitemcinal, 
EM-523, and EM-574 were separately suspended in 3% gum arabic solution. 
 
3.2.5 Statistical Analysis 
All data are expressed as a mean ± SEM. Statistical analysis was performed by using Dunnett’s 
multiple comparison test to compare responses with responses in the corresponding vehicle 
groups. P values less than 0.05 were considered statistically significant. 
 
3.3 Results 
3.3.1 Effects of the Test Drugs on the Gastrointestinal Contractile Activity in 
the Interdigestive State 
Mitemcinal (3 µg/kg) administered i.v. or p.o. in the interdigestive state induced MMC-like 
contractions. In other words, a cluster of strong contractions occurred in the gastric antrum and 
the duodenum, and then migrated to the jejunum (Figure 3-1A and B). The form of these 
contractions was similar to that of spontaneous phase III MMCs (Figure 3-1A and B) and the 
cluster of contractions induced by i.v. administration of pMTL (Figure 3-1C). The MMC-like 
contractions induced by mitemcinal occurred immediately after i.v. administration (Figure 
3-1A), however, approximately 10 min after p.o. administration (Figure 3-1B). 
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Figure 3-1  Typical tracings of the effects of mitemcinal (A, 3 µg/kg i.v.; B, 3 µg/kg 
p.o.) and pMTL (C, 0.3 µg/kg i.v.) on the gastrointestinal contractile activity in 
conscious dogs in the interdigestive state. Solid arrows indicate that mitemcinal 
or pMTL was administered 20 min after the termination of phase III MMCs in the 
gastric antrum in the interdigestive state.  
Typical tracings of the effects of mitemcinal (D, 100 µg/kg i.v.; E, 3,000 µg/kg p.o.) 
and pMTL (F, 3 µg/kg i.v.) on the gastrointestinal contractile activity in conscious 
dogs in the digestive state. Solid arrows indicate that mitemcinal or pMTL was 
administered 2 hours after feeding in the digestive state. Dotted arrows indicate 
the food intake in dogs. 
 
The effects on the gastric antrum MI of i.v. and p.o. administration of mitemcinal (0.3-30 µg/kg), 
EM-523 (0.3-30 µg/kg), EM-574 (0.3-30 µg/kg), and pMTL (0.01-1 µg/kg, i.v. only) are shown 
in Figure 3-2. Mitemcinal, EM-523, and EM-574 increased the gastric antrum MI in a dose-
dependent manner in the same dose range, after both i.v. and p.o. administrations. The dose-
response curves for the gastric antrum MIs induced by all motilin agonists after both i.v. and p.o. 
administrations were parallel (Figure 3-2). The relative potency inducing the gastric contractions 
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after i.v. and p.o. administrations were pMTL > EM574, mitemcinal > EM-523 (Figure 3-2A) 
and mitemcinal > EM574, EM-523 (Figure 3-2B), respectively. 
 
 
Figure 3-2  Effects of mitemcinal, EM-523, EM-574, and pMTL administered i.v. (A) 
or p.o. (B) on the gastric antrum MI in conscious dogs in the interdigestive state. 
Dotted lines in the figures indicate the mean gastric antrum MI due to phase III 
contractions of spontaneous MMCs in conscious dogs. Each point or bar 
indicates the mean ± SEM in 5 dogs. 
 
3.3.2 Effects of a Receptor Agonist and Several Receptor Antagonists on the 
Mitemcinal-Induced Gastrointestinal Contractile Activity in the 
Interdigestive State 
As shown in Figure 3-3, the gastrointestinal contractile activity induced by mitemcinal (3 µg/kg 
i.v.) and pMTL (0.3 µg/kg i.v.) in conscious dogs in the interdigestive state were inhibited by 
continuous i.v. infusion of GM-109, a selective motilin receptor antagonist. Intravenous infusion 
of GM-109, which had no effect on the basal tonus at each gastrointestinal site (Figure 3-3), 
induced rightward shifts in the dose-response curves for mitemcinal and pMTL (Figure 3-4). 
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Figure 3-3  Typical tracings of the effects of GM-109 (1 or 10 mg/kg/hr, i.v. 
infusion) and 0.9% saline on the gastrointestinal contractile activity induced by 
mitemcinal (3 µg/kg i.v., A, B, and C) and pMTL (0.3 µg/kg i.v., D, E, and F) in 
conscious dogs. Mitemcinal or pMTL was administered 10 min after the start of 
i.v. infusion of 0.9% saline or GM-109. 
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Figure 3-4  Effects of GM-109 on dose-response curves showing the gastric 
antrum MI induced by mitemcinal (A) and pMTL (B) in conscious dogs in the 
interdigestive state.  Each point or bar indicates the mean ± SEM in 5 dogs. 
 
The effects of a receptor agonist and several receptor antagonists on the mitemcinal (3 µg/kg 
i.v.)-induced gastric antrum MI are summarized in Table 3-1. Atropine (a muscarinic 
cholinergic antagonist), hexamethonium (a nicotinic cholinergic antagonist), ondansetron (a 5-
hydroxytryptamine3, (5-HT3) antagonist), and dopamine (a dopamine agonist) significantly 
inhibited the mitemcinal-induced gastric antrum MI. Other receptor antagonists, ketanserin (a 5-
HT2 antagonist), phentolamine (an α adrenergic antagonist), and propranolol (a β adrenergic 
antagonist) did not affect the mitemcinal-induced gastric antrum MI (Table 3-1). 
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Table 3-1  Effects of receptor antagonists and an agonist on the mitemcinal (3 mg/kg i.v.)-induced gastric antrum motor 
index (MI) in conscious dogs in the interdigestive state. 
 Dose The gastric antrum  
 Drug Receptor Agonist/antagonist Bolus (mg/kg) + infusion (mg/kg/h) motor Index 
 Vehicle  - - - - 190.7 ± 24.1  
 Atropine Muscarinic Antagonist 0.5 0.5 31.0 ± 12.9*  
 Hexamethonium Nicotinic Antagonist 10 10 49.5 ± 15.7* 
 Phentolamine α Adrenergic Antagonist 2 2 151.7 ± 34.1 
 Propranolol β Adrenergic Antagonist 1 1 176.1 ± 33.3  
 Ketanserin 5-HT2  Antagonist 1 1 217.6 ± 37.7  
 Ondansetron 5-HT3 Antagonist 0.1 0.1 23.2 ± 5.6*  
 Dopamine Dopamine Agonist 1 1 21.1 ± 4.8*  
Each value represents the mean ± SEM in 5 dogs. *P<0.05 compared with the vehicle (0.9% saline) group by Dunnett’s multiple comparison test. 
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3.3.3 Effects of Test Drugs on the Gastrointestinal Contractile Activity in the 
Digestive State 
After feeding, the gastrointestinal contractile activity pattern changed to that of the digestive 
state. That is, spontaneous MMCs disappeared and the low-amplitude contractile activity 
without motor quiescence occurred in the gastric antrum, duodenum, and jejunum (Figure 3-1D, 
E, and F). In the digestive state, the amplitude of the gastric contractions increased immediately 
after i.v. administration of mitemcinal (100 µg/kg), and the increase in the amplitude of the 
contractions in the gastric antrum corresponds well to the contractions induced in the duodenum 
by mitemcinal (Figure 3-1D). Mitemcinal (3,000 µg/kg) also enhanced the amplitude of gastric 
and duodenal contractions when administered p.o. (Figure 3-1E). 
As shown in Figure 3-5A, after i.v. administration of mitemcinal (3-100 µg/kg), the gastric 
antrum MI increased and reached a peak 20 min after administration and attenuated gradually. 
The integrated gastric antrum MI up to 20, 60, and 120 min after i.v. administration of 
mitemcinal (MI0-20 min, MI0-60 min, and MI0-120 min) were calculated. Mitemcinal increased each of 
the integrated gastric MI in a dose-dependent manner, and the significant increase was seen in 
all the integrated gastric MIs at 100 µg/kg (Table 3-2). EM-523 (10-300 µg/kg) and EM-574 (3-
100 µg/kg) administered i.v. also increased the gastric antrum MI (Figure 3-5B and C) with time 
courses similar to that seen with mitemcinal. Significant increases by EM-523 and EM-574 on 
the integrated gastric antrum MI were observed at 300 µg/kg and 100 µg/kg, respectively, in 
MI0-20min and MI0-60min (Table 3-2). After i.v. administration of pMTL (0.1-3 µg/kg), the gastric 
antrum MI also increased and reached a peak 20 min after administration (Figure 3-5D). 
However, the increase in the amplitude of gastric contractile waves was transient even at the 
highest dose (3 µg/kg, Figure 3-1F), and the elevated gastric antrum MI returned to the pre-
dosing level 40 min after administration (Figure 3-5D). PMTL at 1 µg/kg and 3 µg/kg, therefore, 
showed significant increases only in MI0-20min, but not in MI0-60min and MI0-120min (Table 3-2). 
After p.o. administration of mitemcinal (300-3,000 µg/kg), an increase in the gastric antrum MI 
was seen from 40 min after administration (Figure 3-1E and Figure 3-6A). The elevated gastric 
antrum MI continued to the end of the observation period at 120 min after administration of 
mitemcinal (Figure 3-6A). The MI0-60min and MI0-120min, but not MI0-20min, after p.o. 
administration of mitemcinal increased in a dose-dependent manner. Significant increases were 
seen at 1,000 µg/kg in MI0-120min and at 3,000 µg/kg in MI0-60min and MI0-120min (Table 3-3). EM-
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523 (3,000-30,000 µg/kg) and EM-574 (1,000-10,000 µg/kg) administered p.o. also increased 
the gastric antrum MI (Figure 3-6B and C) with time courses similar to that seen with 
mitemcinal after p.o. EM-523 showed significant increases at the 30,000 µg/kg in MI0-60min and 
MI0-120min, however, EM-574 did not reach significant level even at the highest dose (10,000 
µg/kg) on the integrated gastric MIs (Table 3-3). 
Mitemcinal after p.o. administration required 10 times higher dose than that after i.v. 
administration to reach a significant increase in the integrated gastric MI in the digestive state 
(Table 3-2 and Table 3-3). In contrast, EM-523 required 100 times higher dose to show a 
significant increase in the integrated gastric antrum MI after p.o. administration (Table 3-2 and 
Table 3-3). EM-574 after p.o. administration could not show significant increases in the 
integrated gastric MI even at 100 times higher dose than that after i.v. administration (Table 3-2 
and Table 3-3). 
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Figure 3-5  Effects of mitemcinal (A), EM-523 (B), EM-574 (C), and pMTL (D) 
administered i.v. on changes in the gastric antrum MI in conscious dogs in the 
digestive state. Each point or bar indicates the mean ± SEM in 6 dogs. Mitemcinal, 
EM-523, EM-574, pMTL, or 0.9% saline as the corresponding vehicle was 
administered i.v. 2 hours after feeding. 
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Figure 3-6  Effects of mitemcinal (A), EM-523 (B), and EM-574 (C) administered 
p.o. on changes in the gastric antrum MI in conscious dogs in the digestive state. 
Each point or bar indicates the mean ± SEM in 6 dogs. Mitemcinal, EM-523, EM-
574, or 3% gum arabic solution as the corresponding vehicle was administered 
p.o. 2 hours after feeding 
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Table 3-2  Effects of mitemcinal, EM-523, EM-574, and porcine motilin (pMTL) 
administered i.v. on the integrated gastric antrum motor index in conscious dogs 
in the digestive state. 
 The integrated gastric antrum motor index 
Drugs Dose (µg/kg, i.v.) MI0-20 min MI0-60 min MI0-120 min 
Vehicle - 105.18 ± 89.2 307.48 ± 44.16 609.53 ± 89.20 
Mitemcinal 3 113.39 ± 14.61 311.36 ± 23.69 548.54 ± 24.71 
 10 195.23 ± 23.95 449.34 ± 55.97 754.03 ± 91.17 
 30 210.96 ± 21.53 454.47 ± 51.05 747.79 ± 65.80 
 100 344.03 ± 63.72* 642.43 ± 63.22* 1049.45 ± 92.75* 
 
EM-523 10 104.09 ± 8.94 259.21 ± 14.38 444.92 ± 31.29 
 30 186.92 ± 23.29 400.44 ± 45.95 622.61 ± 65.35 
 100 254.70 ± 36.79 527.22 ± 93.59 833.87 ± 107.48 
 300 454.13 ± 93.76* 763.23 ± 189.05* 1071.44 ± 285.71 
 
EM-574 3 171.98 ± 11.12 389.07 ± 18.20 650.28 ± 43.91 
 10 245.39 ± 70.14 582.45 ± 177.89 844.56 ± 227.17 
 30 229.04 ± 31.74 448.22 ± 67.55 791.14 ± 77.00 
 100 364.99 ± 72.59* 724.08 ± 139.95* 972.29 ± 199.28 
 
PMTL 0.1 148.58 ± 18.94 322.86 ± 36.82 517.66 ± 40.69 
 0.3 222.69 ± 68.19 407.96 ± 80.91 609.09 ± 80.55 
 1 258.15 ± 33.63* 463.92 ± 68.71 890.39 ± 222.25 
 3 352.99 ± 40.68* 497.84 ± 71.98 827.90 ± 172.82 
Each value represents the mean ± SEM in 6 dogs. Each drug was administered i.v. 2 hours after 
feeding. *P<0.05 compared with the vehicle (0.9% saline) group by Dunnett’s multiple 
comparison test. 
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Table 3-3  Effects of motilin, mitemcinal, EM-523, and EM-574 administered p.o. 
on the integrated gastric antrum motor index in conscious dogs in the digestive 
state. 
 The integrated gastric antrum motor index 
Drugs Dose (µg/kg, p.o.) MI0-20 min MI0-60 min MI0-120 min 
Vehicle - 112.80 ± 10.64 301.38 ± 21.61 590.39 ± 46.97 
 
Mitemcinal 300 116.34 ± 15.90 308.21 ± 40.77 626.27 ± 54.19 
 1,000 115.58 ± 20.93 397.17 ± 50.45 871.58 ± 81.04* 
 3,000 131.90 ± 22.75 460.32 ± 26.19* 921.14 ± 57.38* 
 
EM-523 3,000 122.08 ± 12.11 331.71 ± 29.67 604.22 ± 55.32 
 10,000 102.75 ± 13.80 357.40 ± 56.25 732.54 ± 141.24 
 30,000 122.20 ± 18.88 466.23 ± 61.07* 987.71 ± 71.51* 
 
EM-574 1,000 116.18 ± 6.12 367.94 ± 54.60 757.25 ± 149.95 
 3,000 115.16 ± 14.61 353.29 ± 48.69 711.11 ± 113.02 
 10,000 113.98 ± 17.67 461.75 ± 83.84 986.27 ± 158.38 
Each value represents the mean ± SEM in 6 dogs. Each drug was administered p.o. 2 hours after 
feeding. *P<0.05 compared with the vehicle (3% gum arabic solution) group by Dunnett’s 
multiple comparison test. 
 
3.4 Discussion 
In the present study, mitemcinal given i.v. and p.o. during the interdigestive state induced strong 
contractions in the stomach and the duodenum, and these contractions migrated to the jejunum 
in a manner similar to that seen with pMTL. The gastric antrum MI was dose-dependently 
increased by mitemcinal given either i.v. and p.o. Intravenous administration of other EMA 
derivatives (EM-523, EM-574) and pMTL also caused motor-stimulating effects in the 
gastrointestinal tract, as previously reported by Inatomi et al. (1989; 1996). Although it has been 
reported that both EM-523 and EM-574 given i.v. and i.d. induced gastrointestinal contractile 
activity in dogs (Inatomi et al., 1989; 1996), the effects of these two compounds after p.o. 
administration have been unclear. In this study, both i.v. and p.o. administration of mitemcinal, 
EM-523, and EM-574 increased the gastric antrum MI in the same dose range, and the dose-
response curves for the effects of all of the test drugs on gastric antrum MI were parallel. This 
means that all of the test drugs preserved their gastrointestinal contractile activity in conscious 
dogs in the interdigestive state, even when administered p.o. 
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In the interdigestive state, continuous i.v. infusion of GM-109, a selective motilin receptor 
antagonist (Takanashi et al., 1995), induced rightward shifts in the dose-response curves for the 
gastric antrum MI induced by mitemcinal and pMTL in conscious dogs. This demonstrated that 
mitemcinal and pMTL stimulated the gastric contractile activity via motilin receptors in 
conscious dogs. To our knowledge, this is the first report which directly demonstrates that the 
motilin receptor antagonist inhibits the motilin agonistic activity of EMA derivatives and pMTL 
in conscious dogs. The result also seems to strongly support the existence of motilin receptors 
and their regulatory effects on gastrointestinal motility in dogs. To date, however, specific 
motilin receptor binding sites have not been detected in the canine gastrointestinal tract using 
homogenates of the smooth muscle cell (Peeters et al., 1988; Satoh et al., 1994). It is also noted 
that pMTL did not induce contractions in in vitro canine gastrointestinal tract preparations 
(Poitras et al., 1987). This means that motilin receptors are unlikely to be present on the smooth 
muscle of the stomach in dogs. 
Itoh and his colleagues (Itoh, 1997; Inatomi et al., 1996; Ohtawa et al., 1993) have reported that 
spontaneous MMCs and motilin agonist-induced MMC-like contractions in the stomach were 
completely suppressed by atropine (a muscarinic cholinergic antagonist), hexamethonium (a 
nicotinic cholinergic antagonist), dopamine (a dopamine agonist), and ondansetron (a 5-HT3 
antagonist) in conscious dogs. It is known that the activation of dopamine D2 receptors on the 
cholinergic nerve inhibits acetylcholine release (Kusunoki et al., 1985). Therefore, it is 
hypothesized that the motilin agonistic mechanism acts through 5-HT3 receptors and that the 
motilin signal is transmitted to the efferent pathway of the vagus nerve to stimulate endogenous 
acetylcholine release in dogs (Itoh, 1997). In the present study, atropine, hexamethonium, 
dopamine, and ondansetron also significantly suppressed the gastric contractions induced by 
mitemcinal, whereas, ketanserin (a 5-HT2 antagonist), phentolamine (an α adrenergic 
antagonist), and propranolol (a β adrenergic antagonist) did not influence the gastric contraction 
induced by mitemcinal. Our previous study clearly demonstrated that mitemcinal had no binding 
affinity to cholinergic receptors (muscarinic M1, M2, M3, and nicotinic receptors), dopamine 
(dopamine D1 and D2 receptors), or 5-HT receptors (5-HT1, 5-HT2, 5-HT3, and 5-HT4 receptors) 
in receptor binding assays (Takanashi et al., 2007). Combining the evidence, it is considered 
that mitemcinal and pMTL may stimulate motilin receptors in 5-HT neurons on vagal or enteric 
neurons, and that the stimulation of 5-HT neurons activates vagal efferent through 5-HT3 
receptors. However, it is likely that adrenergic pathways and 5-HT2 receptors are not involved in 
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the action of mitemcinal. Further investigations of the mechanisms of the gastrointestinal 
contractile activities induced by motilin agonistic agents, such as mitemcinal, are desirable. 
In the present study, during the digestive state, mitemcinal as well as EM-523, EM-574, and 
pMTL given i.v. increased the amplitude of gastrointestinal contractions in conscious dogs. 
However, a higher dose of each test drug was required to achieve the increase in the gastric 
antrum MI in the digestive state than in the interdigestive state. The result is consistent with 
previous reports that motilin agonistic activities by pMTL, EMA, and EMA derivatives were 
attenuated by food intake in conscious dogs (Itoh et al., 1984; Shiba et al., 1995; Tanaka et al., 
1998; Sato et al., 2000). The mechanism to reduce motilin agonistic activities in the digestive 
state has not been well clarified, but it seems that the acidification in the stomach is one of 
possible consideration for this mechanism in dogs. Itoh et al. (1977) and Yamamoto et al. 
(1994) have reported that the acidification of stomach induced by pentagastrin, histamine, or 
feeding inhibited spontaneous MMCs or pMTL-induced contractions. It was also noted that 
famotidine (an H2 receptor antagonist) blocked not only the inhibition of pMTL-induced 
contractions but also gastric acid secretion induced by histamine at the same dose in dogs 
(Yamamoto et al., 1994). Yamamoto et al. (1994) also suggested that the inhibitory mechanism 
of pMTL-induced contractions by gastrin might involve in not only the acidification of stomach 
but also the CCK receptor associated mechanism. It is well known that several hormones like as 
gastrin and histamine are released after feeding (Miner, 2006), then gastric acid secretion is 
stimulated (Yamamoto et al., 1994; Miner, 2006; Sjodin and Nilsson, 1975; Shinchi et al., 1996; 
Williams et al., 1998; Takanashi and Itoh, 1991). Thus, it is considered that the acidification in 
the stomach induced by several stimulants after feeding, at least, may reduce the motilin 
agonistic activity in the present study in dogs. 
After p.o. administration in the digestive state, mitemcinal also increased the amplitude of 
gastrointestinal contractions and the integrated gastric antrum MI (MI0-60min and MI0-120 min) in a 
dose-dependent manner. Mitemcinal showed significant increases in the integrated gastric 
antrum MI from 100 μg/kg and 1,000 μg/kg after i.v. and p.o. administrations, respectively. In 
the digestive state, 10 times higher dose of mitemcinal after p.o. administration than that after 
i.v. administration was required to show the significant effects on the integrated gastric antrum 
MI, even though mitemcinal induced gastric contractions in the same dose range after i.v. and 
p.o. administrations in the interdigestive stage. The reason of this discrepancy is not clear but 
the delay of mitemcinal absorption because of gastric contents after feeding might be one reason. 
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The gastric contractions induced by mitemcinal was observed immediately after i.v. 
administration both in the interdigestive and digestive state, in contrast, mitemcinal-induced 
gastric contractions occurred 10 and 40 min after p.o. administration in the interdigestive and 
digestive state, respectively. The result suggests that mitemcinal administered p.o. induced 
gastric contractions after absorption and also suggests that the absorption of mitemcinal was 
delayed in the digestive state. Pharmacokinetics of mitemcinal after p.o. administration may be 
different between the interdigestive and digestive state. 
In the present study, EM-523 and EM-574 also increased the amplitude of gastrointestinal 
contractions after p.o. administration in the digestive state. However, EM-574 could not show a 
significant effect on the integrated gastric antrum MI even at the highest dose (10,000 μg/kg), 
whereas, the effect of EM-523 was significant at 30, 000 μg/kg. Because the significant effects 
on the integrated gastric antrum MI were seen at 300 μg/kg and 100 μg/kg after i.v. 
administration of EM-523 and EM-574, respectively, 100 times and more than 100 times higher 
doses of EM-523 and EM-574 were required after p.o. administration. It seems that EM-523 and 
EM-574 required more higher doses than that of mitemcinal after p.o. administration, that is, 
mitemcinal was more than 10 times potent than EM-523 and EM-574 when administered p.o. in 
the digestive state. It is suggested that acid-unstable EMA derivatives, such as EM-523 and EM-
574, may diminish motilin agonistic activity because they are rapidly degraded in the acidic 
conditions (Koga et al., 1994; Takanashi et al., 2007).  
Mitemcinal was created and developed as an acid-resistant, non-peptide, motilin receptor 
agonist with high motor stimulating activity in the gastrointestinal tract but no antibacterial 
activity (Koga et al., 1994). We have previously reported the stability of mitemcinal compared 
to EM-523 and EM-574 under several pH conditions at 37°C. Below pH 3.0, EM-523 almost 
completely broke down within 15 min, whereas mitemcinal only slowly broke down, and about 
40% remained in its unchanged form even after 6 hours at pH 2.2 (Koga et al., 1994). 
Furthermore, the contractile responses to EM-523 and EM-574 in rabbits duodenal muscle strips 
were significantly abolished after incubating them in an acidic solution below pH 2.75 for 30 
min. In contrast, the contractile response to mitemcinal was not affected even when incubated in 
an acidic solution of pH 1.20, such as is found in the stomach (Takanashi et al., 2007). In the 
present study, during the digestive state, all the test drugs were administered 2 hours after 
feeding. It is known that gastric acid output reaches a maximum level 1-2 hours after feeding 
and that the pH in the stomach remains below 3 in dogs and humans (Sjodin and Nilsson, 1975; 
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Shinchi et al., 1996; Williams et al., 1998). It is considered that mitemcinal, which possesses 
excellent acid-resistance, may keep its motilin agonistic activity in the stomach even after 
feeding. During the interdigestive state, by contrast, EM-523 and EM-574 increased 
gastrointestinal contractile activity in the same dose-range after both i.v. and p.o administration. 
The basal gastric acid secretion in the interdigestive state in dogs is very low (Takanashi and 
Itoh, 1991) and pH in the stomach is kept higher than five in dogs (Yamamoto et al., 1994). The 
contractile activities by EM-523 and EM-574 in rabbit duodenal strips were not affected after 
incubation in an acidic solution of pH 4.30 (Takanashi et al., 2007). Combining the evidence, it 
is unlikely that EM-523 and EM-574 degraded in the stomach after p.o. administration in the 
interdigestive state. In the present study in the interdigestive state, the relative potency of EM-
574 after p.o. was lower than that after i.v. administration. It is considered that this might occur 
due to the low absorption of EM-574, but not by its acid-unstable property. Thus, the present 
study demonstrates that the acid-resistance of mitemcinal may contribute to its induction of the 
gastrointestinal contractile activity even after p.o. administration in the digestive state.  
Delayed gastric emptying is often considered an important pathophysiological mechanism for 
symptom generation in gastroparesis (Feldman and Schiller, 1983) and functional dyspepsia 
(Talley, 1995). In particular, symptoms of nausea, vomiting, early satiety, and bloating are 
attributed to delayed or abnormal gastric emptying. For this reason, administration of EMA 
derivatives as prokinetic agents has been attempted to treat these symptoms. The rapid 
degradation of EMA derivatives in acidic conditions, such as are found in the stomach, 
diminishes their motilin agonistic activity, so enteric-coated formulations of these EMA 
derivatives were used for p.o. administration in an earlier clinical study (Verhagen et al., 1997). 
It does not seem rational to administer enteric-coated formulations to patients with delayed or 
abnormal gastric emptying. On the other hand, the clinical development program for mitemcinal 
has been investigating the safety and effectiveness of administering a simple tablet p.o. for the 
treatment of gastroparesis. These investigations have demonstrated that mitemcinal improves 
delayed gastric emptying (Fang et al., 2004; Kipnes et al., 2004) and symptoms (McCallum et 
al., 2005; McCallum and Goldstein, 2006) in patients with gastroparesis, even when 
administered p.o. It is considered that the acid-resistance of mitemcinal may have made an 
important contribution to its effectiveness after p.o. administration in the above clinical studies. 
In summary, mitemcinal stimulated the gastrointestinal contractile activity in a dose-dependent 
manner via motilin receptors in conscious dogs. In contrast to EM-523 and EM-574, especially 
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in the digestive state, the gastrointestinal contractile activity stimulated by mitemcinal was well 
preserved after p.o. administration. This suggests that mitemcinal may be useful in the treatment 
of several gastrointestinal disorders involving dysmotility, such as gastroparesis and functional 
dyspepsia, even when administered p.o. 
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3.5 Summary 
The effects of mitemcinal on the gastrointestinal contractile activity were investigated using 
chronically implanted force transducers in conscious dogs and were compared with the effects 
of porcine motilin (pMTL), EM-523, and EM-574. In the interdigestive state, intravenous (i.v.) 
and oral (p.o.) administration of mitemcinal, EM-523, and EM-574 induced the gastrointestinal 
contractile activity in a manner similar to pMTL. The contractile activity caused by mitemcinal 
was suppressed by continuous i.v. infusion of a motilin receptor antagonist. In the digestive state, 
i.v. and p.o. administration of mitemcinal, EM-523, and EM-574 also stimulated the 
gastrointestinal contractile activity. Mitemcinal, EM-523, and EM-574 given i.v. increased the 
gastric contractile activity in a similar dose range; however, mitemcinal was approximately 10 
times more potent than EM-523 and EM-574 when administered p.o. in the digestive state. 
These results indicate that the mitemcinal-induced gastrointestinal contractile activity operates 
via motilin receptors and possesses a higher activity than EM-523 and EM-574 when 
administered p.o. in conscious dogs in the digestive state. Mitemcinal may therefore be useful in 
the treatment of several gastrointestinal disorders involving dysmotility, such as gastroparesis 
and functional dyspepsia, even when administered p.o. 
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4. Mitemcinal, an Orally Active Motilin Receptor Agonist, 
Accelerates Colonic Motility and Bowel Movement in Conscious 
Dogs 
 
4.1 Introduction 
Motilin is a 22-amino acid polypeptide that regulates the migrating motor contractions (MMC) 
in the upper gastrointestinal tract in the interdigestive state (Itoh, 1997). A macrolide antibiotic 
erythromycin A (EMA), a motilin receptor agonist (Peeters, 1993; Itoh, 1997), has also been 
reported to induce MMC-like contractions in the upper gastrointestinal tract of dogs and humans 
when administered at microbial ineffectively low doses (Itoh et al., 1984; Tomomasa et al., 
1986). It is also likely that EMA acts in the lower gastrointestinal tract as well as the upper one, 
since EMA can stimulate colonic motility and can facilitate bowel movement in animals and 
humans (Bradette et al., 1993; Sharma et al., 1995; Shibata et al., 1995; Costa et al., 1997; 
Chiba et al., 2000). Thus, prokinetic activity of EMA may be useful for the treatment for not 
only the upper but also the lower gastrointestinal disorders. However, EMA itself may disrupt 
the intestinal bacterial flora and induce resistance in bacterial strains due to its antibacterial 
activity. For this reason, further efforts to eliminate the antimicrobial activity as well as enhance 
the motilin-like activities produced a large number of derivatives in the hope of ameliorating the 
motility disorders in patients (Ōmura et al., 1987; Faghih et al., 1998). Unfortunately, most of 
the EMA derivatives rapidly degrade in acidic pH such as in the stomach (Koga et al., 1994). 
Mitemcinal ([2S,4R,5R,8R,9S,10S,11R,12R]-9-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-
hexopyranosyl)oxy]-5-ethyl-4-methoxy-2,4,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-
(isopropylmethylamino)-β-D-xylo-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-
14(1)-ene-3,7-dione(E)-2-butenedioic acid salt (2:1)), has been synthesized in an attempt to 
improve acid stability. In this new derivative, internal ketalization of the 12-hydroxy group of 
EMA, which occurs under acidic conditions, is protected by 12-O-methylation, so that the acidic 
stability is greatly increased. Furthermore, small sophisticated modifications in other side chains 
have conferred enhanced motilin activity, making mitemcinal promising as an oral active 
prokinetic agent (Koga et al., 1994). Mitemcinal shows potent motility-stimulating activity in 
the upper gastrointestinal tract of rabbits, dogs, and monkeys via motilin receptors (Koga et al., 
2002). However, the effects of mitemcinal on the lower gastrointestinal tract have not been 
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investigated. In the present study, therefore, the effects of oral administration of mitemcinal on 
colonic motility and bowel movement in conscious dogs were investigated. 
 
4.2 Materials and methods 
4.2.1 Preparation of animals  
A total of 17 Beagle/CSK dogs of either sex (Chugai Research Institute for Medical Science, 
Inc., Shizuoka, Japan) weighing approximately 10 kg were used in this study. All animal 
procedures were conducted in accordance with Chugai Pharmaceutical's ethical guidelines for 
animal care, and all experimental protocols were approved by the Animal Care Committee of 
the institution. 
Twelve of 17 dogs were used for the experiment which measured gastrointestinal contractile 
activity in the interdigestive state. The dog was anesthetized with an intravenous (i.v.) injection 
of pentobarbital sodium (Nembutal, Abbott Labs, Chicago, IL, 30-40 mg/kg). The abdominal 
cavity was opened and 6 force-transducers (F-12IS, Star Medical, Tokyo, Japan) were sutured 
onto the seromuscular layer of the gastrointestinal tract in a direction that made it possible to 
measure circular muscle contractions (Itoh et al., 1978). As shown in Figure 4-1, the force-
transducer implantation sites were the gastric antrum (GA, approximately 3 cm proximal to the 
pyloric ring), the duodenum (D, approximately 3 cm distal to the pyloric ring), the jejunum (J, 
the center between the ligament of Treitz and the ileocecal junction), and three sites in the colon 
(C1, C2, and C3, approximately 5, 15, and 25 cm distal from the ileocecal junction, 
respectively). A silicone tube (Silascon® medical tubing SH No. 1, Kaneka Medics, Osaka, 
Japan) for the oral administration of the drug was placed into the stomach via a small incision 
made in the gastric corpus to avoid stress caused by the oral dosing method. Lead wires of 
force-transducers and the other end of a silicon tube were taken out and fixed onto the skin 
between the scapulae as reported by Itoh et al. (1978). After the abdominal surgery, another 
silicone tube was inserted into the superior vena cava through a branch vein of the external 
jugular vein, and the other end of tube was fixed onto the adjacent skin with silk sutures.  This 
tube was used as a route for i.v. injection and infusion of drugs, respectively. After the operation, 
a jacket protector (Takasaki Gishi, Gunma, Japan) was placed on the dog to protect the lead 
wires and silicon tubes from the dog’s scratching. The dogs were allowed to recover for 2-3 
weeks before the conducting the experiment. 
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Five of 17 dogs were used for the experiment of bowel movement after feeding. Five dogs were 
chronically implanted a silicon tube into the stomach for oral administration of the drug, then 
the experiment was initiated after 2-3 weeks recovery from the surgery. 
 
 
Figure 4-1  Scheme of the recording system of gastrointestinal contractile 
activity and the sites of the force-transducers implanted in the gastrointestinal 
tract in dogs (GA, gastric antrum; D, duodenum; J, jejunum; C1, colon 1; C2, 
colon 2; C3, colon3). 
 
4.2.2 Measurement and analysis of gastrointestinal contractile activity 
The lead wires from the force-transducers were connected to the cable lead wires from an Itoh-
type amplifier (SS-1786, Nihon Kohden, Tokyo, Japan) by means of a tether system (Heavy 
duty double wall 1/2” ID tether 24”, Alice King Chatham Medical Arts, CA, USA) with a slip 
ring (Muromachi Kikai, Tokyo, Japan), it makes for the dog to round freely in the experimental 
cage. Gastrointestinal contractile activity was recorded with a personal computer (PC-9821, 
NEC, Tokyo) using a gastrointestinal motility recording software (Eight Star, Star Medical).  To 
measure motility quantitatively, the motor indexes (MI) of the gastric antrum and each of colon 
sites were calculated by integrating the area between the contractile wave and the baseline every 
10 min, respectively. The MI of the gastric antrum was evaluated based on the assumption that 
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the contraction area is 100 when the maximum contraction of phase III contractions of the 
MMC lasts for 1 minute (Inatomi et al., 1989). The MI of the colon 1, 2, or 3 was evaluated 
based on the assumption that the contraction area is 100 when the maximum contraction after i.v. 
administration of porcine motilin (3 μg/kg) lasts for 1 minute. This dose of porcine motilin 
induced the giant migrating contractions (GMC) in the colon, which had the highest amplitude 
and rapidly migrated distally in the colon of dogs (Karaus and Sarna, 1987). Before starting 
experiments, the calibration of the MI of each gastrointestinal tract in each dog was performed. 
Namely, the highest amplitude of contractions in the phase III contractions of the MMC at the 
gastric antrum was measured in each dog. Separately, each dog was i.v. administered 3 μg/kg of 
porcine motilin once a day for 3 days to obtain a reproducible contractile response in the colon 
of porcine motilin, and the highest amplitude of contractions of each colon site was identified. 
 
4.2.3 Experimental procedure for gastrointestinal contractile activity 
All experiments for measuring gastrointestinal contractile activity were conducted during the 
interdigestive state. Mitemcinal or 3% gum arabic solution as the corresponding vehicle was 
administered orally via the chronically implanted silicon tube into the stomach 20 minutes after 
the end of the phase III contractions of the MMC in the gastric antrum in 6 dogs. The effect of 
mitemcinal was observed throughout 2 hours after administration. To study the contribution of 
motilin receptors to the contractions induced by mitemcinal, GM-109, a selective motilin 
receptor antagonist (Takanashi et al., 1995), was given with a continuous i.v. infusion (1 or 10 
mg/kg/h) via the silicon tube into the superior vena cava with an infusion pump (TE-331, 
Terumo, Tokyo, Japan) in 6 other dogs. The i.v. infusion of GM-109 was started 10 minutes 
after the end of the phase III contractions of the MMC in the gastric antrum, and then 
mitemcinal (1 mg/kg) was orally administered 10 min after the start of i.v. infusion of GM-109.  
The infusion of GM-109 was stopped 60 minutes after administration of mitemcinal. All drugs 
were administered no more than twice per week to each dog, and the interval between the 
administrations was more than 2 days. 
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4.2.4 Bowel movement after feeding 
The dogs were individually housed in experimental cages and given dog food (240 g/animal, 
CD-5, CLEA Japan, Tokyo, Japan) once a day at 9:00 am. Preliminary to the study, the 
spontaneous bowel movement patterns of 5 dogs after feeding were investigated for 14 days 
prior to the start of this experiment. As a result, more than 64% of spontaneous bowel 
movement events occurred within one hour after food intake. In order to reduce the bias against 
the spontaneous bowel movement after feeding, therefore, dogs were fed at 9:00 am and 
mitemcinal (0.3, 1, or 3 mg/kg) or 3% gum arabic solution as the corresponding vehicle was 
administered orally at 10:00 am only when dogs had the spontaneous bowel movement within 
one hour after feeding. The incidence of bowel movement within 5 hours after mitemcinal or 
3% gum arabic solution administration was identified. If the dog had a bowel movement within 
5 hours, the stool form was graded into three consistency levels as follows: normal stool, stool 
maintains shape; soft stool, all or part of the stool is a soft block with clear-cut edges; diarrhea 
stool, stool is muddy and/or watery. 
 
4.2.5 Drugs 
Mitemcinal and GM-109 were synthesized in our organic chemistry laboratory. Porcine motilin 
was purchased from Peptide Institute, Inc. (Osaka, Japan). For i.v. administrations, porcine 
motilin and GM-109 were dissolved and diluted with 0.9% physiological saline and given i.v. 
bolus injection at a volume of 0.2 mL/kg and i.v. infusion at a volume of 5 mL/kg/h, 
respectively. For oral administrations, mitemcinal was prepared by suspending in 3% gum 
arabic solution, and given to dogs orally at a volume of 0.5 mL/kg. 
 
4.2.6 Statistical analysis 
The incidence of bowel movement within 5 hours was analyzed by the chi-squared test. Other 
results were expressed as means ± SEM and statistical analysis was performed by Dunnett’s test. 
The dose-dependent effect of mitemcinal was evaluated using a Jonckheere-Terpstra test. P 
values less than 0.05 were considered statistically significant. 
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4.3 Results 
4.3.1 Effect of mitemcinal on gastrointestinal contractile activity in the 
interdigestive state 
As shown in Figure 4-2A, oral administration of 3% gum arabic solution as the corresponding 
vehicle of mitemcinal had no effect on the spontaneous gastrointestinal contractile activity 
pattern in conscious dogs. Namely, the Phase III contractions of the MMC regularly occurred at 
gastric antrum and the duodenum in the interdigestive state; they migrated to the jejunum. In the 
colon, clusters of small contractions, called the colonic motor complexes (CMC, Bickel and 
Belz (1988)), were occurring during all the time without any silent period independently from 
the MMC that occurred in the upper gastrointestinal tract. Mitemcinal at an oral dose of 
0.1mg/kg induced strong contractions at the upper gastrointestinal tracts, but there were no 
obvious changes in colonic motility at any site (Figure 4-2B). When mitemcinal at doses of 0.3 
or 1 mg/kg were orally administered, strong contractions at all sites of the colon were observed. 
These contractions lasted for approximately 30 and 60 min after 0.3 and 1 mg/kg administration, 
respectively (Figure 4-2C and D). 
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Figure 4-2  Typical tracings of gastrointestinal contractile activity in the 
interdigestive state in conscious dog after oral administration of 3% gum arabic 
solution as the corresponding vehicle (A), 0.1mg/kg (B), 0.3 mg/kg (C), and 1 
mg/kg (D) of mitemcinal. The corresponding vehicle and mitemcinal were 
administered at the point indicated by the arrow, respectively. 
 
The effects on the MI by oral administration of mitemcinal at 10-minute intervals are shown in 
Figure 4-3. At the gastric antrum, the MI significantly increased in a dose-dependent manner 
after oral administration of mitemcinal with a minimum effective dose of 0.1 mg/kg. The peak 
increase of the MI was observed at 20 min and a significant increase in the MI lasted for 2 hours 
after administration at all doses (Figure 4-3A). Mitemcinal also significantly increased the MI of 
all three sites of the colon in a dose-dependent manner (Figure 4-3B, C, and D). The major 
difference in the response to mitemcinal in each of the colon sites was not demonstrated. 
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Figure 4-3  The motor index (MI, 10-min intervals) of the gastric antrum (A), the 
colon 1 (B), colon 2 (C), and colon 3 (D) in the interdigestive state in conscious 
dogs after oral administration of mitemcinal or 3% gum arabic solution as the 
corresponding vehicle. Each point represents mean ± SEM from 6 dogs. *P<0.05, 
compared with the corresponding vehicle group by Dunnett’s test. 
 
4.3.2 Contribution of motilin receptors on mitemcinal-induced 
gastrointestinal contractile activity in the interdigestive state 
The i.v. continuous infusion of GM-109 (1 or 10 mg/kg/h), a motilin receptor antagonist, alone 
induced temporal contractions in the gastric antrum in some dogs (Figure 4-4B and C); however, 
it did not affect the basal MI of each gastrointestinal site in dogs (Figure 4-5B and C). 
As shown in Figure 4-4A and Figure 4-5, a strong enhancement of gastrointestinal contractile 
activity was observed in the upper and the lower gastrointestinal tracts after oral administration 
of mitemcinal (1 mg/kg) under the continuous i.v. infusion of 0.9% physiological saline as the 
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corresponding vehicle of GM-109. However, the acceleratory effects of mitemcinal on colonic 
contractile activity at all sites were partially and completely inhibited by treatment with the 
continuous infusion of GM-109 at a dose of 1 and 10 mg/kg/h, respectively (Figure 4-4B, C, 
Figure 4-5B, C, and D). At the gastric antrum, even though the frequency of contractile waves 
seemed to be reduced by infusion of GM-109 (Figure 4-4B and C), the mitemcinal-induced MI 
of the gastric antrum was not completely inhibited even in the presence of higher doses of GM-
109 (Figure 4-5A). The inhibitory effect of GM-109 on mitemcinal-induced gastrointestinal 
contractile activity disappeared immediately after i.v. infusion of GM-109 was stopped. That is, 
high amplitude contractions occurred at small and large intestinal sites and the frequency of the 
contractions at the gastric antrum was increased immediately after the termination of the i.v. 
infusion of GM-109 (Figure 4-4B, C and Figure 4-5). In the colon, especially, high amplitude 
and rapid propagating contractions occurred, and then some dogs had a bowel movement 
(Figure 4-4B and C). 
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Figure 4-4  Typical tracings of gastrointestinal contractile activity in the 
interdigestive state in conscious dogs after oral administered mitemcinal (1 
mg/kg) with continuous infusion of 0.9% physiological saline as the 
corresponding vehicle of GM-109(A), 1 mg/kg/h (B), and 10 mg/kg/h (C) of GM-109. 
Mitemcinal was administered at the point indicated by the arrow and GM-109 was 
infused from 10 min prior to 60 min after the mitemcinal administration. 
 
Chapter IV: Effect of mitemcinal on colonic motility 
69 
 
Figure 4-5  The motor index of the gastric antrum (A), the colon 1 (B), colon 2 (C), 
and colon 3 (D) after mitemcinal (1 mg/kg p.o.) in the interdigestive state in 
conscious dog with or without GM-109 continuous infusion. Each point 
represents mean ± SEM from 6 dogs. *P<0.05, compared with the corresponding 
control group by Dunnett’s test. 
 
In order to evaluate the inhibitory effect of GM-109 throughout 1 hour, the MI of each 
gastrointestinal site accumulated within 1 hour after oral administration of mitemcinal is shown 
in Table 4-1. The MI of each colon site was significantly inhibited by GM-109 in a dose-
dependent manner. At the higher dose of GM-109 (10 mg/kg/h), the MI of each the colon site 
was the same as the MI of the basal level of the CMC, whereas the MI of the gastric antrum was 
partially inhibited (Table 4-1).  
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Table 4-1  The accumulated Motor Index (MI) in the gastric antrum and three sites 
of the colon within 1 hour after oral administration of mitemcinal (1mg/kg) under 
the continuous i.v. infusion of GM-109. 
 GM-109 (mg/kg/h i.v. infusion) 
Region 0 (vehicle) 1 10 Basala 
Gastric antrum 1190.2 ± 72.8 641.7 ± 73.1* 628.7 ± 87.7* ─ 
Colon 1 788.8 ± 120.0 393.5 ± 50.3* 284.5 ± 54.8* 238.8 ± 35.6 
Colon 2 526.0 ± 13.0 281.6 ± 47.0* 160.1 ± 17.5* 175.3 ± 17.2 
Colon 3 533.6 ± 131.7 252.2 ± 60.0* 154.2 ± 23.8* 169.9 ± 23.2 
Each value represents the mean ± SEM of 6 dogs. *P<0.05 compared with the corresponding 
vehicle group by Dunnett’s test. 
a Basal value represents the motor index for 1 hour prior to the start of i.v. infusion of GM-109 
because colonic motor complexes (CMC) are occuring in the all sites of the colon independently 
from the MMC in the upper gastrointestinal tract. 
 
4.3.3 Effects of mitemcinal on bowel movement after feeding 
In the interdigestive state described above, the bowel movement was observed in 1, 5 and 5 of 6 
dogs after administration of 0.1, 0.3, and 1 mg/kg of mitemcinal, respectively within 2 hours 
after administration. However, the bowel movement was also observed in 4 of 6 vehicle treated 
dogs. In the interdigestive condition, the spontaneous bowel movement possibly veiled the 
effect of mitemcinal on the bowel movement; therefore, the effect of mitemcinal on the bowel 
movement was examined after feeding. 
After feeding, all dogs had the bowel movement within 5 hours after administration at the 
highest dose of mitemcinal (3 mg/kg), even though no dog had a bowel movement in the 
corresponding vehicle group within 5 hours (Table 4-2). The time to the first bowel movement 
after the highest dose of mitemcinal was 220 ± 17 min (n=5, 167-265 min) and this effect of 
mitemcinal was significant compared with the vehicle group (Table 4-2). Two of 5 dogs also 
had a bowel movement after administration in a dose of 1 mg/kg mitemcinal at 201, 277 min 
after administration, respectively (Table 4-2). The stool conditions of the bowel movement after 
mitemcinal administration were all normal or soft stools.  Namely, mitemcinal did not induce 
diarrhea in dogs. 
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Table 4-2  Numbers of dogs that had a bowel movement within 5 hours after oral 
administration of mitemcinal and stool forms.  
 Latency period 
 Dose Total <5 hours Stool form 
Drugs  (mg/kg)  Dogs (n) Dogs (n)  P values*  (Normal, Soft, Diarrhea) 
Vehicle ─ 5 0 ─ (0, 0, 0) 
Mitemcinal 0.3 5 0 P = 1.0000 (0, 0, 0) 
Mitemcinal 1 5 2 P = 0.1138 (1, 1, 0) 
Mitemcinal 3 5 5 P = 0.0016 (2, 3, 0) 
*No. of dogs with bowel movement from vehicle and dosing groups were compared using chi-
square test. 
 
4.4 Discussion 
The present study demonstrates that mitemcinal dose-dependently stimulated not only the upper 
but also the lower gastrointestinal contractile activity in the interdigestive state via motilin 
receptors in conscious dogs even after oral administration. Oral administration of mitemcinal 
also accelerated bowel movement after feeding in dogs. 
In the present study, orally administered mitemcinal stimulated colonic contractile activity in a 
dose-dependent manner with a minimum effective dose of 0.3 mg/kg in the interdigestive state 
in conscious dogs. The present study also demonstrates that mitemcinal accelerated colonic 
contractile activity in all three sites simultaneously at the same doses. The result is consistent 
with the previous report that there was no regional difference in the effects of colonic motility 
by i.v. infusion of motilin in conscious dogs (Shibata et al., 1995). Bickel and Belz (1988) also 
demonstrated that i.v. injection of motilin induced the colonic GMC in the entire right colon in 
dogs. On the other hand, the upper gastrointestinal contractile activity was strongly induced by 
mitemcinal from the lowest dose (0.1 mg/kg) in the present study, although mitemcinal induced 
no obvious changes in the colonic contractile activity at any site in the lowest dose.  Similar 
results in conscious dogs have been demonstrated that low dose motilin (0.2 μg/kg/hr, i.v. 
infusion) only increased gastric antral motility; more than 5 times higher doses of motilin were 
required to increase colonic motility in the interdigestive state (Shibata et al. 1995). Inatomi et 
al. (1993) also reported that EM-523, one of the EMA derivatives, administered i.v. infusion at 
30 μg/kg/h could induce stronger MMC-like contractions in the gastric antrum, but failed to 
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induce colonic motor activity in conscious dogs. There may be a difference in sensitivity to 
motilin and motilin receptor agonists between the gastric antrum and the colon in dogs. 
The consideration of the different sensitivity of motilin agonists between in the gastric antrum 
and the colon may be supported by the result of the present study using a selective motilin 
receptor antagonist, GM-109. In the present study, mitemcinal-induced contractile activities in 
the gastric antrum and the colon were significantly inhibited by the treatment with GM-109, 
indicating that mitemcinal stimulates gastric and colonic motility via motilin receptors in the 
interdigestive state in conscious dogs. Although the higher dose of GM-109 (10 mg/kg/h i.v. 
infusion) completely abolished mitemcinal-induced contractile activity in all sites of the colon 
by the basal level of the CMC, the inhibition by GM-109 in the gastric antrum was still partial. 
One possible explanation is that the higher dose of GM-109 used in this study was merely 
insufficient for completely inhibiting the mitemcinal (1 mg/kg, orally)-induced gastric antral 
motility. Our previous study (Koga et al., 2002) demonstrated that gastric antral motility 
induced by a lower dose of mitemcinal was completely inhibited by GM-109 at 10 mg/kg/h i.v. 
infusion. 
Another possible explanation may be that the contractile activity of mitemcinal on the gastric 
antrum has some resistance to the inhibition manner by GM-109. It is generally accepted that 
the final mediator of the action of motilin agonists must be acetylcholine in the stomach because 
the spontaneous MMC and motilin agonists-induced MMC-like contractions in the stomach 
were completely abolished by atropine or hexamethonium in dogs (Itoh, 1997). Otherwise, it 
was reported that the contractions induced by motilin in the colon of conscious dogs were 
abolished by atropine but were not affected by the hexamethonium (Shibata et al., 1995). Taken 
together, there are some regional differences in the mechanism of the contractions induced 
motilin agonists in the gastrointestinal tract in dogs and these differences may have contributed 
to the difference of the mitemcinal or GM-109 sensitivity. Further investigations on the 
mechanism of gastrointestinal contractile activity induced by the motilin agonists are desirable 
In the interdigestive state in conscious dogs, it seemed that it was difficult to examine the effect 
of mitemcinal on bowel movement because of the spontaneous bowel movement. In the present 
study, therefore, the effect of mitemcinal on bowel movement was examined after feeding, that 
is, in the digestive state. Because the spontaneous bowel movement event mostly occurred 
within 1 hour after feeding in the digestive state, it was possible to reduce the bias against the 
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spontaneous bowel movement by using only dogs that had a spontaneous bowel movement 
within 1 hour after feeding. In this condition, mitemcinal reduced the time to the first bowel 
movement after oral administration without inducing diarrhea in dogs. Even though the higher 
dose of mitemcinal was required for bowel movement after feeding than that for stimulating 
colonic motility in the interdigestive state, it is well known that much less effects of motilin 
were shown after feeding (Itoh, 1990). Hirabayashi et al. (2005) demonstrated that oral 
administration of mitemcinal at a dose of 3 mg/kg increased colonic motility even in the 
digestive state in conscious dogs. It is suggested that the stimulating activities on colonic 
motility by the motilin agonistic mechanism could facilitate bowel movement in dogs. 
Furthermore, the evidence that motilin agonists induce less contractile activity in the colon of 
dogs suggests that the MMC-like contractions in the upper gastrointestinal tract by mitemcinal 
may also contribute to the colonic movement. 
The present study suggests that mitemcinal may be a new therapeutic agent for treatment of 
lower as well as upper gastrointestinal disorders including constipation due to bowel 
dysfunction in the clinical setting. It has been reported that exogenous motilin and EMA could 
stimulate colonic motility and increase the frequency of the bowel movements in clinical studies 
(Peeters, 1993; Bradette et al., 1993; Sharma et al., 1995). In contrast, others reported that 
exogenous EMA failed to effectively stimulate colonic motility in healthy volunteers (Jameson 
et al., 1992). These controversial results for EMA may be, at least in part, attributable to its 
antibacterial activity to the intestinal bacterial flora, low potency as a motilin agonist or 
overdoses. Thus, the development of novel EMA derivatives with higher activity and without 
antibacterial activity like mitemcinal is encouraged. 
In conclusion, oral administration of mitemcinal accelerates colonic motility along with the 
upper gastrointestinal motility via motilin receptors in conscious dogs. Mitemcinal administered 
orally also facilitated bowel movement in dogs. It is considered that the facilitation of bowel 
movement by mitemcinal may be reflected by the direct stimulation of colonic motility and 
indirect contribution of the upper gastrointestinal MMC to the colon. Thus, mitemcinal could be 
a promising agent for treatment of lower as well as upper gastrointestinal motility disorders, 
including constipation. 
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4.5 Summary 
The prokinetic effects of mitemcinal, an orally active motilin receptor agonist, on the lower 
gastrointestinal tracts were investigated in conscious dogs. Oral administration of mitemcinal 
(0.1-1 mg/kg) stimulated colonic motility, which was measured by chronically implanted force-
transducers, as well as gastric motility in a dose-dependent manner. The gastrointestinal 
contractile activities induced by mitemcinal were inhibited by the continuous intravenous 
infusion of GM-109, a selective motilin receptor antagonist. Oral administration of mitemcinal 
(0.3-3 mg/kg) also accelerated bowel movement after feeding without inducing diarrhea in dogs. 
The results demonstrate that mitemcinal stimulates colonic motility via motilin receptors and the 
effect of mitemcinal on colonic motility may reflect bowel movement after feeding. Thus, 
mitemcinal could be a promising agent for treatment of not only the upper but also the lower 
gastrointestinal motility disorders. 
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5. Effects of Motilin and Mitemcinal on the Gastrointestinal 
Contractile Activity in Rhesus Monkeys in Vivo and in Vitro 
 
5.1 Introduction 
Motilin, a 22-amino acid residue peptide, was first characterized and isolated from porcine small 
intestinal mucosa (Brown et al., 1971). Since then, motilin has been discovered in several other 
animals including humans. Human motilin has the same sequence as porcine motilin, and differs 
by 3 amino acid residuals from rabbit motilin and by 5 amino acid residuals from both canine 
and cat motilin (Itoh, 1997). 
It is well known that there are several species differences in the action of motilin. For example, 
in in vitro studies, motilin induced concentration-dependent contractions of rabbit duodenum 
strips and human stomach, but did not induce contractions in rat or guinea-pig tissues (Strunz et 
al., 1976; 1975). Receptor binding assays of rabbit and human gastrointestinal tissue 
homogenates demonstrated specific binding to motilin, indicating that motilin receptors are 
present in the gastrointestinal tracts of these species (Bormans et al., 1986; Peeters et al., 1988), 
but receptor binding assays of similarly prepared dog tissue homogenates did not demonstrate 
the presence of motilin receptors (Peeters et al., 1988). In in vivo studies, exogenous motilin 
induced migrating motor complex (MMC)-like contractions in dogs and humans (Itoh et al., 
1976; Vantrappen et al., 1979), but the activity of motilin in rabbits differed from that seen in 
dogs and humans in that although intravenous (i.v.) administration of motilin increased 
contractile activity in the upper gastrointestinal tract in rabbits, the contractions did not migrate 
distally (Guerrero-Lindner et al., 1996). 
The mode of action of motilin has not been well clarified; it is not known whether motilin acts 
through intrinsic neurons, extrinsic neurons, or smooth muscles; and it is likely that the actions 
of motilin and its mechanisms differ under different experimental conditions (e.g. in vivo 
experiments, isolated strips, and isolated whole organs) even in the same animal species. In dogs, 
for example, the spontaneous MMC and motilin-induced MMC-like contractions were 
completely abolished by atropine and hexamethonium in the stomachs of conscious dogs, so the 
final motilin mediator would seem to be acetylcholine released from the vagus nerve in the dog 
stomach (Itoh, 1997). Motilin agonist-induced MMC-like contractions in the dog stomach are 
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also antagonized in vivo by systemic treatment with 5-HT3 antagonists (Yoshida et al., 1991; 
Haga et al., 1996). It is known that the area postrema is very rich in fenestrated capillaries and 
has numerous neurons including 5-HT neurons in the perivascular spaces around capillaries 
(Leslie, 1986), so it is generally believed that motilin agonists may stimulate motilin receptors in 
5-HT neurons in the area postrema, and that stimulation of 5-HT neurons activates vagal 
efferents through 5-HT3 receptors (Itoh, 1997). So far, however, the existence of motilin 
receptors in the area postrema has not been demonstrated. On the other hand, isolated canine 
duodenum strips were not contracted by porcine motilin, and were contracted by canine motilin 
only when treated with nonphysiological high concentrations (Poitras et al., 1987). The 
contractile response to canine motilin in the canine duodenum was resistant to tetrodotoxin and 
atropine, but was sensitive to verapamil (Poitras et al., 1987). Motilin caused phasic 
contractions in isolated canine stomach independently of the presence of extrinsic nerves, and 
these contractions were significantly inhibited by atropine and hexamethonium (Mizumoto et al., 
1993). 
It has been reported that erythromycin A (EMA), a macrolide antibiotic, acts as a motilin 
receptor agonist (Itoh, 1997; Itoh et al., 1984; Peeters, 1993). As a result of efforts to eliminate 
the antimicrobial activity and enhance the motilin agonistic activity of EMA, a large number of 
derivatives, such as EM-523 (Ōmura et al., 1987), EM-574 (Tsuzuki et al., 1989), and ABT-229 
(Li et al., 2004), have been produced in the hope of finding a treatment for motility disorders 
such as gastroparesis (Itoh, 1997; Peeters, 1993). The preclinical studies for most of the above 
compounds have mainly used dogs (in vivo) and rabbits (in vitro) (Peeters, 1993). Because there 
are several differences in the actions of motilin in different species and under different 
experimental conditions, as described above, it may be difficult to predict the effects of EMA 
derivatives in humans based on preclinical results in dogs or rabbits. 
The present study was conducted to test the hypothesis that motilin reactivity is similar in 
monkeys and humans. This hypothesis is based on the fact that the sequence of the monkey 
motilin has been found to be only one amino acid different from that of human motilin (Huang 
et al., 1998). Since there have been no reports of motilin reactivity in monkeys, the present 
study was designed to investigate the actions of motilin and mitemcinal on the Rhesus monkey 
gastrointestinal tract, both in vivo and in vitro. Mitemcinal ([2S,4R,5R,8R,9S,10S,11R,12R]- 9-
[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-5-ethyl-4-methoxy-
2,4,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(isopropylmethylamino)-β-D-xylo-
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hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-14(1)-ene-3,7-dione(E)-2-butenedioic 
acid salt (2:1)) is an EMA derivative that was synthesized in our laboratory (Peeters, 2001). It 
was reported that mitemcinal acted as a selective and full motilin receptor agonist in the smooth 
muscle of the rabbit small intestine (Takanashi et al., 2007). Clinical trials of mitemcinal in 
patients with diabetic gastroparesis are currently underway (McCallum et al., 2005; McCallum 
and Goldstein, 2006). 
 
5.2 Materials and methods 
5.2.1 Animals 
Male Rhesus monkeys (approximately 5 kg, Chugai Research Institute for Medical Science, Inc., 
Shizuoka, Japan) and male Japanese-White Rabbits/CSK (approximately 2-3 kg, Chugai 
Research Institute for Medical Science) were used in this study. The monkeys were individually 
housed in experimental cages and given monkey diet (PS 120 g/body, Oriental Yeast Co., 
Tokyo, Japan) and one piece of banana once a day at 4:00 pm. All animal procedures were 
conducted in accordance with Chugai Pharmaceutical's ethical guidelines for animal care, and 
all experimental protocols were approved by the Animal Care Committee of the institution. 
 
In Vivo Investigations: 
5.2.2 Measurement of gastrointestinal contractile activity in conscious 
monkeys 
Animals were anesthetized with an intramuscular injection of ketamine (15 mg/kg, Sankyo-Yell 
Yakuhin Co., Tokyo, Japan) and an i.v. injection of pentobarbital (15 mg/kg, Abbott Labs, 
Chicago, IL). Prior to the start of surgery, atropine (50 µg/kg, Tanabe Seiyaku, Osaka, Japan) 
was injected i.v. to prevent salivation and gastrointestinal motility. The abdomen was opened 
and force transducers (F-12IS [8 × 13 mm] and F-8IS [5 × 8 mm], Star Medical Inc., Tokyo, 
Japan) were sutured at the following locations in orientations that enabled measurement of 
circular muscle contractions: the gastric antrum (F-12IS, 3 cm proximal to the pyloric ring), the 
duodenum (F-8IS, 3 cm distal from the pyloric ring), and the jejunum (F-8IS, 30 cm distal from 
the pyloric ring). After the above abdominal surgery, a silicon tube (602-205, Dow Corning, 
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Midland, MI) for i.v. administration of drugs was implanted into the vena cava via the right 
external jugular vein, and the lumen of the tube was filled with heparinized 0.9% saline solution. 
After a 2- to 3-week recovery period, the gastrointestinal contractile activity in the conscious 
monkeys was recorded using a thermal pen recorder (WR3701, Graphtec Corporation, Tokyo, 
Japan) through an Itoh-type amplifier (SS-1786, Nihon Kohden, Tokyo, Japan) by connecting 
cable lead wires from the amplifier to the lead wires of the force transducers. The contractile 
activity signal from the gastric antrum was also input to a signal processor (7T, Nihon 
Kohden/NEC San-Ei Instruments, Tokyo, Japan), and quantitative analysis was performed by 
calculating the motor index (MI) as the area between the contractile wave and the baseline. The 
MI of the gastric antrum was evaluated based on the assumption that the contraction area is 100 
when maximal phase III contractions of the MMC continue for 1 min (Inatomi et al., 1989). 
Porcine motilin (Sigma Chemical Co., St. Louis, MO) and mitemcinal (synthesized in our 
organic laboratory) were dissolved in 0.9% saline and administered i.v. about 15 min after the 
end of the MMC cycle in the gastric antrum via the silicon tube implanted into the vena cava. 
To examine the effects of several blockers on the contractile activity induced by porcine motilin, 
GM-109, a selective motilin receptor antagonist synthesized in our laboratory (Takanashi et al., 
1995), was administered by continuous i.v. infusion from 5 min prior to 10 min after porcine 
motilin administration at a rate of 0.25 μmol/kg/min, and atropine (0.3 μmol/kg, a muscarinic 
antagonist) and hexamethonium (10 μmol/kg, Sigma Chemical, a nicotinic antagonist) were 
injected i.v. 5 min prior to the administration of porcine motilin. The effective dose of atropine 
used in this study have been confirmed to be appropriate for examining the effect of atropine on 
contractile activities induced by i.v. administration of bethanechol (3 μmol/kg, Sigma Chemical, 
dissolved in 0.9% saline). 
 
5.2.3 Measurement of the gastric emptying rate in conscious monkeys 
Before the start of each experiment, the animals were acclimated to the oral administration 
procedure to avoid stress caused by the administration method. That is, each animal was 
restrained on a monkey chair and a feeding tube (6 Fr Atom Medical Co., Tokyo, Japan) was 
inserted into its stomach from the nose every day for 7 days. The gastric emptying rate of 
monkeys was measured by the acetaminophen (AAP) method (Heading et al., 1973) after 
overnight fasting. The monkey was restrained in a monkey chair and 10 mL/kg of liquid meal 
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(Okunos Liquid Food A, 14.5% carbohydrate, 5.1% protein, 2.8% lipid, 240 J/mL; Forica Foods 
Co., Niigata, Japan) thoroughly mixed with 40 mg/mL of AAP (Wako Pure Chemical Industries, 
Osaka, Japan) was administered orally via the trans-nasal feeding tube. Blood samples (0.5 mL) 
were collected with a heparinized syringe from the cubital vein every 15 minutes from 0 to 90 
minutes, and every 30 minutes from 90 to 180 minutes, after administration of the liquid meal. 
The concentration of AAP in the plasma of the blood samples was measured by HPLC. The 
peak plasma concentration, time to peak concentration, and AUC0-60 of AAP were calculated. 
Porcine motilin, mitemcinal, or 0.9% saline as the corresponding vehicle was administered i.v. 5 
min after administration of the liquid meal. In each animal each experiment was conducted at 
intervals of at least 1 week.  
 
In Vitro Investigations: 
5.2.4 Motilin receptor binding assay using gastrointestinal tissue 
homogenates 
The binding investigation was performed by the method of a previously reported study in rabbits 
(Bormans et al., 1986), with minor modifications. Each monkey was anesthetized with ketamine 
and pentobarbital, as described above, and euthanized by exsanguination via the carotid artery. 
After exsanguination, the gastrointestinal tract of the monkey was rapidly removed, rinsed with 
ice-cold 0.9% saline, and separated into various gastrointestinal tract regions, as follows. The 
stomach was divided into three regions from the proximal to the distal end as the fundus, the 
corpus, and the antrum. The small intestine (total length, about 1.5 m) was divided into three 
regions from the proximal to the distal end as the duodenum, the jejunum, and the ileum. For the 
colon (total length, about 70 cm), 50 cm of the proximal side was used in the study. Connective 
tissue and the mucosal layer were removed from each segment, and the remaining tissue was 
homogenized in 50 mM Tris-HCl buffer (pH 7.4) at 0°C using a tapered homogenizer (Model 
358115; Wheaton Science, Millville, NJ). The homogenate was centrifuged (TMP-22; Hitachi 
Koki Co., Ltd, Tokyo, Japan) at 1500 g for 5 min and then washed twice with fresh Tris-HCl 
buffer (50 mM, pH 7.4). The final pellet was re-suspended in 50 mM Tris-HCl buffer (pH 8.0, 
containing 10 mM MgCl2 and 1.5% bovine serum albumin) for the binding investigation. The 
homogenate was incubated at 25°C for 120 min with 25 pM 125I-porcine motilin (Peninsula 
Laboratories Inc., Belmont, CA) made up to 1 ml. After incubation, the reaction was stopped by 
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adding 2 ml of ice-cold buffer. Bound and free reagents were separated by centrifugation at 
1500 g for 5 min. The pellet was washed with ice-cold buffer, and its radioactivity was 
determined using a gamma counter (ARC-300; Aloka, Tokyo, Japan). 
Specific binding was defined as the difference between total and nonspecific binding after the 
addition of 1 μM porcine motilin. First, the ratio of specific to total binding of 125I-porcine 
motilin in each region of the gastrointestinal tract was examined. Second, displacement curves 
were obtained by adding increasing amounts of porcine motilin, canine motilin (Sigma 
Chemical Co.), mitemcinal, or GM-109 to the duodenum tissue incubation sample, and the 
concentrations that reduced specific binding by 50% (IC50) were found. All of the procedures, 
from isolation of the tissue to incubation, were performed under ice-cold conditions. 
To compare the affinities of motilin ligands for motilin receptors in monkey and rabbit tissue, 
displacement curves for porcine motilin, mitemcinal, and GM-109 were also obtained using 
rabbit duodenal tissue homogenates prepared by the above method. 
 
5.2.5 Contractile activity in isolated monkey duodenum muscle strips 
Monkeys were anesthetized and euthanized by the above method. The upper part of the small 
intestine was rapidly removed after laparotomy and placed in ice-cold modified Krebs’ solution 
composed of (in mM): NaCl 120.0, KCl 4.7, CaCl2 2.4, KH2PO4 1.0, MgSO4 1.2, NaHCO3 24.5, 
and glucose 5.6 (pH 7.4). The duodenum was washed, freed from mesenteric attachment, and 
cut along the longitudinal axis to obtain muscle strips about 10 mm long and 3 mm wide. The 
strips were then mounted in an organ bath containing 10 mL of modified Krebs’ solution kept at 
28°C. The solution was gassed with a mixture of 95% O2 and 5% CO2. The longitudinal strips 
were initially loaded with a 1.0 g weight, and contractile activity was measured by isotonic 
transducers (ME-4012; Medical Electronics Co., Tokyo, Japan) and recorded on an ink-writing 
recorder (Type 3066; Yokogawa-Denki, Tokyo, Japan). Before the experiments, each strip was 
subjected to repeated stimulation with 100 μM acetylcholine (Dai-ichi Pharmaceutical Co., 
Tokyo, Japan) until a reproducible response was obtained, and then porcine motilin or 
mitemcinal was added cumulatively to the organ bath. To normalize the data, the contractile 
potency of each agonist was expressed as a percentage of that induced by 100 μM acetylcholine. 
To examine the influences of atropine and verapamil (Ca channel blocker, Sigma Chemical Co.) 
on the contraction induced by porcine motilin, isolated duodenum strips were treated for 15 min 
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with either atropine (1 μM) or verapamil (1 μM). The contractile response induced by porcine 
motilin (30 nM) in the absence or presence of each blocker was compared. All drug 
concentrations are expressed as final molar (M) concentrations in the bath solution. 
5.2.6 Statistical Analysis 
All data were expressed as the mean ± SEM. Statistical analysis was performed using Dunnett’s 
multiple comparison test. P values less than 0.05 were considered statistically significant. 
 
5.3 Results 
5.3.1 Spontaneous gastrointestinal contractile activity in conscious 
monkeys 
Typical tracings of spontaneous gastrointestinal contractile activity patterns are shown in Figure 
5-1. In the interdigestive state, MMC occurred regularly in the gastric antrum and duodenum 
and then migrated to the jejunum. After feeding, the contractile activity pattern changed to the 
digestive state, that is, MMC disappeared and small irregular contractions occurred in the gastric 
antrum, duodenum, and jejunum. The spontaneous MMC pattern in the interdigestive state was 
measured for 10 days in 4 animals. MMC lasting 25 ± 1 min started at 928 ± 25 min after 
feeding, and reoccurred every 120 ± 5 min. The mean MI of the gastric antrum was 158.3 ± 13.5. 
The observational results are summarized in Table 5-1. 
Figure 5-1  Typical tracings of the gastrointestinal contractile activity in the 
interdigestive state (A) and the digestive state (B) in a conscious monkey. GA: 
gastric antrum, D: duodenum, J: jejunum. Horizontal bar shows 1 hour. 
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Table 5-1  Spontaneous contractions in conscious monkeys. 
 Monkey No. Duration of feeding stage MMC interval MMC duration MMC MI in the GA 
 mean (min.-max.) (min) mean (min.-max.) (min) mean (min.-max.) (min) mean (min.-max.) 
 1 938 ± 29 (784-1086) 152 ± 14 (39-268) 25 ± 2 (12-51) 176.7 ± 33.6 (73.4-381.5) 
 2 922 ± 63 (480-1140) 112 ± 11 (41-328) 19 ± 1 (8-33) 192.3 ± 33.7 (40.0-381.6) 
 3 1008 ± 27 (841-1158) 110 ± 11 (54-251) 28 ± 2 (11-69) 103.8 ± 9.9 (44.5-143.0) 
 4 844 ± 58 (436-1129) 116 ± 6 (42-205) 27 ± 1 (11-62) 160.1 ± 11.2 (113.2-231.0) 
 Average 928 ± 25 (436-1158) 120 ± 5 (39-328) 25 ± 1 (8-69) 158.3 ± 13.5 (40.0-381.6) 
Each value represents the mean ± SEM with the minimum and maximum values shown in parentheses. 
Duration of feeding stage (min): Time from feeding to the start of the first MMC cycle in the gastric antrum.  
MMC interval (min): Time between two MMC cycles in the gastric antrum, measured from the start of one cycle to the start of the 
next cycle.  
MMC duration (min): Duration of each MMC cycle in the gastric antrum. 
MMC MI in the GA: The motor index of the MMC in the gastric antrum.
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5.3.2 Effects of drugs on the gastrointestinal contractile activity in 
conscious monkeys in the interdigestive state  
Intravenous injection of porcine motilin (≥0.3 nmol/kg) or mitemcinal (≥30 nmol/kg) induced 
MMC-like contractions similar to the spontaneous MMC in the upper gastrointestinal tract 
(Figure 5-2A and B). The MI of the gastric antrum was increased by porcine motilin and 
mitemcinal in a dose-dependent manner (Figure 5-2C). The gastric contractile activity induced 
by porcine motilin was completely inhibited by continuous i.v. infusion of GM-109 (Figure 
5-3A). The contractile activity induced by porcine motilin was significantly inhibited by 
pretreatment with hexamethonium, but not by pretreatment with atropine (Figure 5-3A). The 
contractile activity induced by bethanechol was not inhibited by hexamethonium but was 
completely abolished by atropine (Figure 5-3B). 
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Figure 5-2  Effects of i.v. administration of porcine motilin (A, 0.3 nmol/kg) or 
mitemcinal (B, 100 nmol/kg) on the gastrointestinal contractile activity in 
conscious monkeys. GA: gastric antrum, D: duodenum. Horizontal bar shows 5 
min.  
Dose-response curves for i.v. injection of porcine motilin (●, 0.1-10 nmol/kg) or 
mitemcinal (○, 10-300 nmol/kg) on the motor index (MI) of the gastric antrum in 
conscious monkeys in the interdigestive state (C). Each point represents the 
mean ± SEM of 4 animals. The dotted line shows the mean MI of the gastric 
antrum from the spontaneous MMC of 4 animals. 
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Figure 5-3  Effects of atropine, hexamethonium, and GM-109 on the motor index 
(MI) of the gastric antrum induced by porcine motilin (0.3 nmol/kg, A) or 
bethanechol (3 μmol/kg, B) administered i.v. to conscious monkeys. Each 
column represents the mean ± SEM of 3 to 4 animals. Atropine (0.3 μmol/kg) or 
hexamethonium (10 μmol/kg) were injected i.v. 5 min before administration of 
porcine motilin or bethanechol. GM-109 (0.25 μmol/kg/hr) was given by 
continuous i.v. infusion from 5 min prior to 10 min after administration of porcine 
motilin. *P<0.05 compared with each agonist alone (control) group by Dunnett’s 
test. 
 
5.3.3 Effects of porcine MTL and mitemcinal on the gastric emptying rate in 
conscious monkeys 
Porcine motilin (0.1-1 nmol/kg) and mitemcinal (30-300 nmol/kg) given i.v. 5 min after 
ingestion of a liquid meal thoroughly mixed with AAP dose-dependently decreased the time to 
peak AAP concentration, increased the peak AAP concentration, and increased the AUC0-60 of 
AAP (Figure 5-4 and Table 5-2). 
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Figure 5-4  Changes of plasma concentration of AAP (mg/mL) after oral 
administration of a liquid meal (10mL/kg) containing 40 mg/mL AAP. Porcine 
motilin (○: 0.1 nmol/kg, ∆: 0.3 nmol/kg, □: 1 nmol/kg) (A) or mitemcinal (○: 30 
nmol/kg, ∆: 100 nmol/kg, □: 300 nmol/kg) (B) were administered i.v. 5 min after 
the liquid meal administration. As the corresponding vehicle, 0.9% physiological 
saline (●) was administered i.v. Each point represents the mean ± SEM of 6 
animals. 
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Table 5-2  Peak concentration, time to peak concentration, and AUC0-60 of acetaminophen (AAP) in conscious monkeys 
after administration of a liquid meal containing 40 mg/mL AAP. 
 Drug Dose Peak concentration of AAP Time to peak concentration AUC0-60 
 (nmole/kg) (μg/mL) (min) (μg×min/mL) 
 Porcine motilin Vehicle 7.5 ± 1.2 105.0 ± 9.5 136.2 ± 19.7 
 0.1 10.4 ± 2.0 30.0 ± 10.2* 446.7 ± 93.8 
 3 14.7 ± 4.2 48.5 ± 18.7* 612.1 ± 184.9* 
 1 13.8 ± 2.0 25.0 ± 7.4* 586.5 ± 72.9* 
 
 Mitemcinal Vehicle 10.3 ± 1.0 92.5 ± 11.2 222.1 ± 60.5 
 30 12.0 ± 1.7 85.0 ± 7.4 379.6 ± 75.7 
 100 15.4 ± 1.4 52.5 ± 12.1 556.9 ± 75.0 
 300 27.2 ± 4.3* 37.5 ± 8.4* 1064.7 ± 137.3* 
Each value represents the mean ± SEM of 6 observations in 6 animals. Porcine motilin, mitemcinal, or 0.9% saline as the corresponding vehicle 
was administered iv 5 min after ingestion of the liquid meal.  
*P<0.05 compared with the corresponding vehicle group by Dunnett’s test. 
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5.3.4 Motilin receptor binding assay in monkeys   
Preliminary to the study, the distribution of motilin receptors in the gastrointestinal tract was 
examined by assay of each region. The ratio of specific to total binding of 125I-porcine motilin in 
each region is shown in Figure 5-5A. Specific binding of motilin was observed in the gastric 
antrum, duodenum, jejunum, and ileum; but was not confirmed in the gastric fundus, corpus, or 
colon. The highest ratio of specific to total binding of motilin was observed in the duodenum, so 
the duodenum muscle tissue was used in the following investigation. 
The effects of several motilin ligands on the binding of 125I-porcine motilin to monkey 
duodenum homogenate were investigated. The displacement curves obtained by adding 125I-
porcine motilin and increasing concentrations of porcine motilin, canine motilin, mitemcinal, 
and GM-109 to monkey duodenal tissue are shown in Figure 5-5B; all of these curves are 
parallel. The IC50 values for porcine motilin, canine motilin, mitemcinal, and GM-109 are 
shown in Table 5-3. 
 
5.3.5 Motilin receptor binding assay in rabbits   
The displacement curves for porcine motilin, mitemcinal, and GM-109 in the motilin receptor 
binding investigation using rabbit duodenal tissue were also parallel (data not shown). The IC50 
values are summarized in Table 5-3.  
 
Table 5-3  IC50 values for motilin receptors in monkey and rabbit duodenal tissue 
homogenates. 
 Ligand IC50 value (nM)  
 Monkey (N) Rabbit (N) 
 Porcine motilin 2.8 ± 1.4 (5) 0.9 ± 0.1 (5) 
 Canine motilin 1.6 ± 0.5 (3) Not tested 
 Mitemcinal 14.8 ± 10.1 (5)  4.9 ± 0.9 (5) 
 GM-109 65.5 ± 7.7 (4) 10.8 ± 0.1 (5) 
Each value represents the mean ± SEM. 
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Figure 5-5  Distribution of motilin receptors along the gastrointestinal tract in 
Rhesus monkeys (A).  Binding experiments were performed with homogenates of 
the gastric fundus (Fun), corpus (Cor), antrum (Ant), duodenum (Duo), jejunum 
(Jej), ileum (Ile), and colon (Col). Each column represents the mean of 2 
experiments.  
Displacement of 125I-porcine motilin binding in monkey duodenal tissue by 
porcine motilin (●), canine motilin (○), mitemcinal (∆), and GM-109 (□) (B). Each 
point represents the mean ± SEM of 3 to 5 experiments. 
 
5.3.6 Effects of drugs on the contractile activity in isolated monkey duodenal 
strips 
Porcine motilin (1-1,000 nM) and mitemcinal (30-10,000 nM) induced contractions in isolated 
duodenal longitudinal muscle strips of monkeys in a concentration-dependent manner (Figure 
5-6A, B, and C). The maximum contractions of duodenal strips caused by porcine motilin and 
mitemcinal were 72.3 ± 4.1% and 53.8 ± 6.5% (percentages of the contraction caused by 100 
μM of acetylcholine; both N=8) (Figure 5-6C). The contractions induced by both agonists were 
diminished by the addition of 10 μM of GM-109 (Figure 5-6A and B). The contractions induced 
by porcine motilin were not affected by pretreatment with 1 μM atropine, but were completely 
inhibited by pretreatment with 1 μM verapamil (Figure 5-6D). 
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Figure 5-6  Typical tracings of contractions induced by porcine motilin (A) and 
mitemcinal (B) in isolated monkey duodenal longitudinal muscle strips. Numbers 
show the molar concentration of each drug in the organ bath. Horizontal bar 
shows 10 min.  
Concentration-response curves for porcine motilin (●, 1-1,000 nM) and 
mitemcinal (○, 30-10,000 nM) in isolated monkey duodenal longitudinal muscle 
strips (C). The ordinate scale represents the percentage of the contraction 
induced by 100 μM acetylcholine. Each point represents the mean ± SEM of 8 
strips.  
The effects of atropine (1 μM) and verapamil (1 μM) on the contraction induced 
by porcine motilin (30 nM) in isolated monkey duodenal longitudinal muscle 
strips (D). Each column represents the mean ± SEM of 3 to 5 strips. *P<0.05 
compared with porcine motilin alone (control) group by Dunnett’s test. 
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5.4 Discussion 
The findings of the present study were 1) spontaneous MMC similar to those in dogs and 
humans occurred in conscious monkeys in the interdigestive state, and 2) motilin and 
mitemcinal (an EMA derivative) induced contractions in the gastrointestinal tract of monkeys, 
both in vivo and in vitro, as in humans. To the best of our knowledge, this is the first report of 
the motilin-induced gastrointestinal contractile activity in monkeys. 
In the present study, two gastrointestinal contractile activity patterns were observed in conscious 
monkeys: an interdigestive pattern and a digestive pattern. These patterns were very similar to 
those seen in dogs (Itoh et al., 1976) and humans (Vantrappen et al., 1979). Porcine motilin and 
mitemcinal administered i.v. to conscious monkeys in the interdigestive state dose-dependently 
induced strong contractions similar to the spontaneous MMC in the gastric antrum and 
duodenum. The contractions induced by porcine motilin were completely abolished by 
continuous i.v. infusion of GM-109, indicating that porcine motilin induces gastrointestinal 
contractions via motilin receptors in conscious monkeys. It is clear that motilin regulates 
spontaneous MMC in dogs and humans because the peak plasma endogenous motilin 
concentration coincides with the end of the MMC cycle in the stomach and duodenum in both 
species (Itoh, 1997). Many investigators have also reported that exogenous administrations of 
motilin and EMA induced MMC-like contractions in the stomach and duodenum of dogs and 
humans (Itoh et al., 1984; Peeters, 1993; Tomomasa et al., 1986). Taken together, the results of 
the present study may suggest that motilin regulates the MMC cycle in the interdigestive state in 
conscious monkeys, as in dogs and humans. 
It has been reported that motilin agonist-induced MMC-like contractions in the stomach are 
atropine-sensitive in conscious dogs. It is therefore hypothesized that the final mediator of 
motilin in the dog stomach is acetylcholine released from the vagus nerve (Itoh, 1997). In 
humans, motilin-induced gastric contraction was atropine-sensitive but motilin-induced 
duodenal contraction was atropine-resistant (Bovin et al., 1997). In the present study, 
surprisingly, gastric contractions induced by porcine motilin in conscious monkeys were not 
inhibited by atropine. The dose of atropine used in the present study was considered sufficient to 
inhibit the muscarinic mechanism because contractions induced by bethanechol (a 
cholinomimetic) were completely inhibited by the same dose of atropine. Motilin may induce 
gastric contractions in conscious monkeys directly via motilin receptors in the smooth muscle of 
the stomach. The existence of motilin receptors in the gastric antrum of monkeys was confirmed 
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in the present binding investigation. However, the contraction induced by porcine motilin was 
significantly inhibited by hexamethonium, indicating that the contractile mechanisms of porcine 
motilin in the stomach of monkeys also involve a neuronal pathway. The results therefore 
suggest that the mechanisms of motilin activity in conscious monkeys act via two different 
pathways. 
It has been demonstrated that motilin receptors exist in the gastrointestinal neural and muscle 
layers in humans and rabbits. Motilin receptors in nerves and smooth muscle have different 
affinity to some motilin ligands, suggesting that motilin receptors may belong to different 
receptor subtypes (Miller et al., 2000a; 2000b). In isolated rabbit stomach, low doses of motilin 
(0.1-10 nM) enhanced contractions induced by electric stimulation via motilin receptors in the 
nerves in an atropine-sensitive manner, whereas high doses of motilin (over 10 nM) induced 
contractions directly by activation of motilin receptors in smooth muscle in an atropine-resistant 
manner (Van Assche et al., 1997). To identify the mechanism by which motilin induces 
gastrointestinal contraction in monkeys, it would be desirable to further examine the influence 
of several pharmacological antagonists on the responses induced by different doses of motilin. 
Because motilin and mitemcinal induced gastrointestinal contractions in conscious monkeys, the 
effects of motilin and mitemcinal on the gastric emptying rate were investigated in the present 
study using an AAP method. It is known that AAP is not absorbed from the stomach but is 
absorbed rapidly from the small intestine, so its blood concentration is well correlated with the 
gastric emptying rate (Heading et al., 1973). The present study demonstrated that porcine 
motilin and mitemcinal administered i.v. in a similar dose range to induce the gastrointestinal 
contractile activity dose-dependently decreased time to peak AAP concentration, increased peak 
AAP concentration, and increased AAP AUC0-60. These results suggest that porcine motilin and 
mitemcinal accelerated the gastric emptying rate by increasing gastrointestinal contractile 
activity via a motilin agonistic mechanism. On the other hand, it is known that increased gastric 
motility does not necessarily lead to an accelerated gastric emptying rate because it has been 
reported that intraduodenal administration of a high dose of cisapride (3 mg/kg) to dogs 
increased gastric antral motor activity but delayed gastric emptying (Tanaka et al., 1998). It is 
considered that well-coordinated gastrointestinal contractions within the gastric antrum and the 
duodenum may be important for the acceleration of gastric emptying (Tanaka et al., 1998). The 
results of this study suggest that a motilin agonistic mechanism may induce physiological 
gastrointestinal contractile activity that accelerates gastric emptying in monkeys. 
Chapter V: Prokinetic effect of motilin in monkeys 
93 
In the present study, specific binding of motilin was demonstrated in the gastric antrum, 
duodenum, jejunum, and ileum; but not in the gastric fundus, corpus, or colon. Although the 
quantitative analysis was not sufficient, the motilin receptor density seems to be highest in the 
duodenum. The presence of motilin receptors has been confirmed in several animals, including 
rabbits (Bormans et al., 1986), cats (Depoortere et al., 1993b), and humans (Peeters et al., 1988), 
but a motilin receptor binding study did not demonstrate the presence of motilin receptors in 
dogs (Peeters et al., 1988). The distribution of motilin receptors in the upper gastrointestinal 
tract in monkeys was similar to that previously reported in rabbits, cats, and humans (Bormans 
et al., 1986; Peeters et al., 1988; Depoortere et al., 1993b). Those reports demonstrated that 
motilin receptor densities in the stomach and the small intestine, respectively, are highest in the 
gastric antrum and the duodenum, and that the motilin receptor density in the small intestine 
decreases aborally. There are, however, species differences in relation to the colon: in cats, no 
motilin receptor was not detected in the colon, whereas in rabbits, motilin receptors were about 
4 times denser in the colon than in the duodenum (Depoortere et al., 1991). The results of the 
present study indicate that the distribution of motilin receptor in monkeys is closer to that seen 
in the cat than to that seen the rabbit. 
The present study also demonstrates that several different types of motilin ligands such as 
porcine and canine motilins (poly-amino-acid peptides), GM-109 (a cyclic tetrapeptide), and 
mitemcinal (an EMA derivative) bind to motilin receptors in the duodenal muscle tissue of 
monkeys. The order of affinities of these ligands was consistent with those found in the rabbit 
motilin receptor binding investigation in this study. It seems that the binding of motilin 
receptors to several types of motilin ligands in monkeys is similar to that in rabbits. However, 
the present study also revealed several differences between monkeys and rabbits with respect to 
the IC50 values of motilin ligands. The IC50 value for porcine motilin in monkey tissue was 2.8 ± 
1.4 nM, which is about 3 times higher than in rabbit tissue (0.9 ± 0.1 nM) at the same 125I-
porcine motilin concentration. Higher IC50 values were seen in monkey motilin receptors, not 
only for porcine motilin but also for mitemcinal and GM-109, indicating that the affinity of 
motilin ligands to motilin receptors is lower in monkeys than in rabbits. Differences between 
rabbits and humans with respect to the affinity of motilin ligands to motilin receptors have also 
been reported previously. The Kd value of motilin receptors in human gastric antrum smooth 
muscle (1.8 nM) was about 3 times higher than in rabbits (0.53 nM) (Depoortere et al., 1990). 
Taken together, it seems that monkey and human motilin receptors have weaker affinities to 
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motilin ligands than rabbit motilin receptors, indicating that the characteristics of motilin 
receptors may be similar in monkeys and in humans. 
In the present study, porcine motilin and mitemcinal also induced contractions in isolated 
monkey duodenum strips in a concentration-dependent manner. These contractions were 
inhibited by treatment with GM-109, indicating that porcine motilin and mitemcinal induced 
contractions of the duodenum strips via motilin receptors. It has been reported that motilin-
induced contractions in human or rabbit in vitro specimens were not affected by atropine, 
tetrodotoxin, or hexamethonium, but were inhibited by verapamil or by removing Ca2+ from the 
medium (Strunz et al., 1976; 1975). The effect of tetrodotoxin on contractions induced by 
porcine motilin was not tested, but the results of the present study confirm that, as in humans 
and rabbits, motilin-induced contractions in the monkey duodenum were atropine-resistant and 
verapamil-sensitive. 
The maximum contractions induced by porcine motilin and mitemcinal, respectively, in isolated 
monkey duodenal muscle strips were 72.3 ± 4.1% and 53.8 ± 6.5% of the contraction induced 
by 100 μM acetylcholine (both N=8). In rabbit duodenal muscle strips, however, both porcine 
motilin and mitemcinal induced maximal contractions of 100% of that induced by 100 μM 
acetylcholine (Takanshi et al., 2007; Clark et al., 1999). Furthermore, the concentrations of 
porcine motilin and mitemcinal which induced maximal contractions in the monkey duodenal 
muscle strips were about 10 times higher than those that induced maximal contractions in the 
rabbit duodenal strips (Takanshi et al., 2007; Clark et al., 1999). Depoortere et al. compared the 
effect of porcine motilin and EM-523 in human and rabbit duodenal strips (Depoortere et al., 
1990). According to them, both porcine motilin and EM-523 induced contractions in human and 
rabbit duodenal muscle strips in a concentration-dependent manner, but the concentrations of 
porcine motilin and EM523 required to induce maximal contraction were about 10-100 times 
higher for human tissue than for rabbit tissue. They also reported that porcine motilin and EM-
523 induced smaller maximal contractions than acetylcholine in human strips. It is therefore 
considered that the contractions caused by the motilin agonistic mechanism in monkeys in vitro 
may resemble those seen in humans more closely than those seen in rabbits. 
The present study was conducted to test the hypothesis that motilin reactivity is similar in 
monkeys and humans. In conclusion, the study results demonstrated that monkeys react to 
motilin both in vivo and in vitro, and that motilin induces contractions in the monkey 
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gastrointestinal tract in the same as in humans, both in vivo and in vitro. The only difference 
between monkeys and humans observed in the present study was that the contraction induced by 
porcine motilin in conscious monkeys was not suppressed by atropine. Although it would be 
desirable to identify the detailed mechanisms of the action of motilin in monkeys, the present 
study has demonstrated that the monkey is useful for the study of the pharmacological and 
physiological roles of motilin and motilin-related compounds because it shows reactivity to 
motilin both in vivo and in vitro. 
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5.5 Summary 
Neither the presence of motilin receptors nor their action has been investigated in monkeys. The 
object of this study was to determine the effects of motilin and mitemcinal, an erythromycin 
derivative, on the gastrointestinal tract in Rhesus monkeys in vivo and in vitro. In in vivo 
investigations in conscious monkeys, both motilin and mitemcinal induced migrating motor 
complex-like contractions in the interdigestive state and also accelerated gastric emptying. In in 
vitro investigations, the presence of motilin receptors in the gastrointestinal tract was 
demonstrated by receptor binding assays. Motilin and mitemcinal contracted isolated duodenum 
strips in a concentration-dependent manner. In conclusion, Rhesus monkeys may be useful for 
studying the physiological and pharmacological roles of the motilin agonistic mechanism 
because they show reactivity to motilin both in vivo and in vitro. 
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Concluding remarks 
Summary 
Based on the acid-decomposiotion mechanism of EMA, an acid-resistant EMA derivative, 
mitemcinal, was designed. Comprehensive pharmacological evaluations of mitemcinal 
conducted in the present studies have clearly demonstrated that mitemcinal is a selective, acid-
resistant, orally active motilin agonist. The results suggest that mitemcinal may be useful in the 
treatment of several gastrointestinal disorders with dysmotility even when administered orally. 
 
At first, in Chapter I, it was demonstrated that GM-109 is a selective motilin receptor ligand that 
lacks agonistic properties but acts as a pure antagonist in rabbits. Thus, GM-109 was used for 
the subsequent examinations as a useful pharmacological tool. 
 
In Chapter II, the pharmacological profiles of mitemcinal was investigated using smooth muscle 
of the rabbit small intestine and the results demonstrated that mitemcinal is a selective and full 
motilin receptor agonist in vitro and that this agent has an excellent acid-resistant property. 
 
In Chapter III, since an excellent acid-resistant property besides a selective and powerful motilin 
agonistic activity of mitemcinal had been proved in in vitro study, then the efficacy of 
mitemcinal in in vivo was investigated. It was demonstrated that mitemcinal-induced 
gastrointestinal contractile activity operates via motilin receptors and possesses a higher activity 
than other EMA derivatives (EM-523 and EM-574) when administered orally in the digestive 
state (higher acidic condition) in conscious dogs. 
 
In Chapter IV, the effects of oral administration of mitemcinal on colonic motility and bowel 
movement besides the prokinetic effect of mitemcinal on upper gastrointestinal tract were 
investigated in conscious dogs. The results demonstrated that mitemcinal stimulates colonic 
motility via motilin receptors and accelerates bowel movement after feeding. 
 
Finally, in Chapter V, it was demonstrated that, both motilin and mitemcinal induced MMC-like 
contractions in the interdigestive state and also accelerated gastric emptying in conscious 
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monkeys. In in vitro investigations, the presence of motilin receptors in the gastrointestinal tract 
was demonstrated and motilin and mitemcinal contracted isolated duodenum strips. Thus, 
Rhesus monkeys may be useful for studying the physiological and pharmacological roles of the 
motilin agonistic mechanism because they show reactivity to motilin both in vivo and in vitro. 
 
In conclusion, our data reveals that mitemcinal behaves as a powerful motilin receptor agonist in 
in vitro and in vivo investigation (with focusing on upper gastrointestinal tract) with an acid-
resistant property. This suggests that mitemcinal may be useful in the treatment of several 
gastrointestinal disorders with dysmotility, such as gastroparesis and functional dyspepsia, even 
when administered orally. Mitemcinal also showed prokinetic activity on the lower 
gastrointestinal tracts, namely mitemcinal could be a promising agent for treatment of lower as 
well as upper gastrointestinal motility disorders, including constipation. In addition, the present 
study has demonstrated that the monkey is useful for the study of the pharmacological and 
physiological roles of motilin and motilin-related compounds. Monkey may give us the answers 
to the many quests, the detailed mechanisms of the action of motilin and several motilin receptor 
agonists. 
 
Future prospects 
In the present studies, all investigations were carried out using normal animals and demonstrated 
the potential of mitemcinal. However, the efficacy of mitemcinal in disease conditions remains 
unclear. The results derived from the examination in delayed gastric emptying models (chemical 
or diabetes-induced) and constipated model will give us much more useful information. On the 
other hands, since human motilin receptor (GPR38) was cloned, the development of a cell line 
expressing the cloned human motilin receptor opened new perspectives for research on motilin 
and motilin receptor agonists. I hope this new technique and animal experiments synergistically 
expand the motilin and motilin receptor agonist’s research. 
 
To date, unfortunately, no EMA derivative has been approved as medicine for patients with 
gastrointestinal disorders with dysmotility, such as gastroparesis, functional dyspepsia, and 
constipation. I hope this type of drug will be delivered to patients as soon as possible and being 
able to improve their Quality of Life. 
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